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The ubiquitin system regulates the majority of cellular processes in eukaryotes.  26	
Ubiquitin is ligated to substrate proteins as monomers or chains and the topology 27	
of ubiquitin modifications regulates substrate interactions with specific proteins.  28	
Thus ubiquitination directs a variety of substrate fates including proteasomal 29	
degradation1.  Deubiquitinase enzymes cleave ubiquitin from substrates and are 30	
implicated in disease2; for example ubiquitin-specific protease-7 (USP7) regulates 31	
stability of the p53 tumor suppressor and other proteins critical for tumor cell 32	
survival3.  However, developing selective deubiquitinase inhibitors has been 33	
challenging4 and no co-crystal structures have been solved with small molecule 34	
deubiquitinase inhibitors.  Here, using nuclear magnetic resonance (NMR)-based 35	
screening and structure-based drug design, we describe the development of 36	
selective USP7 inhibitors GNE-6640 and GNE-6776.  These compounds induce 37	
hematopoietic and solid tumor cell death and enhance cytotoxicity with 38	
chemotherapeutic agents and targeted compounds, including PIM kinase 39	
inhibitors.  Structural studies reveal that GNE-6640 and GNE-6776 non-covalently 40	
target an interface between the thumb, fingers, and palm regions of the USP7 41	
catalytic domain, 12Å distant from the catalytic cysteine.  The compounds 42	
attenuate ubiquitin binding and thus inhibit USP7 deubiquitinase activity.  Within 43	
the USP7 thumb region, GNE-6640 and GNE-6776 interact with acidic residues that 44	
mediate H-bond interactions with the ubiquitin Lys-48 side-chain5, suggesting that 45	
USP7 preferentially interacts with and cleaves ubiquitin moieties having free Lys-46	
48 side-chains.  We investigated this idea by engineering di-ubiquitin chains 47	
containing differential proximal and distal isotopic labels and measuring USP7 48	
binding via NMR, a study that substantiated our hypothesis.  This preferential 49	
binding significantly protracted the depolymerization kinetics of Lys-48-linked 50	
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ubiquitin chains relative to Lys-63-linked chains.  In summary, engineering 51	
compounds that inhibit USP7 activity by attenuating ubiquitin binding suggests 52	
opportunities for developing other deubiquitinase inhibitors and may be a strategy 53	
more broadly applicable to inhibiting proteins that require ubiquitin binding for full 54	
functional activity. 55	
 56	
USP7 is a genetically-validated deubiquitinase for MDM2, a ubiquitin ligase that 57	
promotes degradation of the tumor suppressor p53.  Depletion of USP7 enhances 58	
ubiquitination of USP7 substrates, including MDM2.  Subsequent MDM2 proteasomal 59	
degradation stabilizes the p53 tumor suppressor, thus promoting cell cycle arrest and 60	
apoptosis.  USP7 inhibition enhances ubiquitination of additional USP7 substrates that 61	
also contribute to cell growth inhibition3,6,7 (Fig. 1a).  To identify USP7 inhibitors, we 62	
established a high throughput activity-based screening (HTS) cascade, consisting of a 63	
primary deubiquitinase assay followed by a series of counter-screen assays and 64	
selection filters (Supplementary Information Fig. 1a, 1b).  In parallel we developed an 65	
NMR fragment screening cascade to identify fragments that bind the USP7 catalytic 66	
domain at discrete sites (Supplementary Information Fig. 1c).  A hit-to-lead selection 67	
cascade was established to guide optimization of HTS and NMR hits into more potent 68	
USP7 inhibitors (Fig. 1b).  At the apex of this cascade, deubiquitinase selectivity assays 69	
and structural biology directed medicinal chemistry design.  Additionally, assays to 70	
measure total- and ubiquitinated-MDM2 levels were developed as proximal indicators of 71	
USP7 cellular activity, followed by cellular viability assays using inactive compounds 72	
from the same chemical series as negative controls (Fig. 1a, 1b). 73	
 74	
Progression of HTS and NMR screening hits through the hit-to-lead selection cascade 75	
identified a series of fragment compounds as having the most favorable properties for 76	
on-target efficacy (Supplementary Information Figs. 2-5).  Optimization of the parent 77	
compound GNE-2916 yielded GNE-6640 and GNE-6776.  These USP7 inhibitors 78	
enhanced endogenous MDM2 ubiquitination while achieving selectivity over USP47, the 79	
most USP7-homologous deubiquitinase, and USP5, a highly-expressed and active 80	
deubiquitinase8 (Extended Data Fig. 1a).  Both compounds accelerated endogenous 81	
MDM2 turnover, that was apparent in combination with cycloheximide, a necessary co-82	
treatment since MDM2 is a p53 target gene (Fig. 1a, 1c, Extended Data Fig. 1b).  83	
Accordingly, both GNE-6640 and GNE-6776, but not control compounds GNE-2118 and 84	
GNE-6641, promoted endogenous MDM2 ubiquitination with Lys-48 (K48)-linked 85	
polyubiquitin chains that direct proteins for proteasomal degradation9 (Fig. 1d, Extended 86	
Data Fig. 1c).  The active USP7 inhibitors stabilized p53 and upregulated p21 in wild-87	
type cells, but not in p53-null cells, and did not further elevate p53 and p21 expression in 88	
USP7-null cells (Fig. 1e, Extended data Fig. 1b).  These data were corroborated by a 89	
significant dose-dependent decrease in viability of wild-type, but not of USP7-null cells, 90	
treated with either inhibitor at concentrations ≤15µM (Extended data Fig. 1d).  GNE-6640 91	
also increased p53 and p21 levels and decreased viability to a greater extent in breast 92	
adenocarcinoma and osteosarcoma cell lines compared to normal primary breast 93	
epithelial cells or osteocytes (Extended Data Fig. 2a, 2b).  Thus the collective data 94	
indicate that GNE-6640 and GNE-6776 regulate cellular USP7/MDM2/p53 signaling 95	
pathways. 96	
 97	
A study by Ritorto et al. revealed that previously-reported deubiquitinase inhibitors are 98	
neither potent nor sufficiently selective when evaluated at 1-10µM in a MALDI-TOF mass 99	
spectrometry-based assay4.  In this assay, GNE-6640 and GNE-6776 inhibited USP7 100	
cleavage of di-ubiquitin chains and were highly selective against 36 other recombinant 101	
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deubiquitinases at 10µM (Fig. 2a, Extended Data Fig. 3a).  GNE-6776 remained 102	
selective even at 100µM, a >6-fold higher concentration than used in cellular assays, 103	
whereas control compound GNE-6641 had negligible activity at either concentration (Fig. 104	
2a, Extended Data Fig. 3b).  Since deubiquitinase activities are regulated by numerous 105	
cellular mechanisms10 we developed an assay utilizing activity-based probes to evaluate 106	
USP7 inhibitor effects on endogenous deubiquitinases (Heideker et al., manuscript in 107	
preparation).  Both GNE-6640 and GNE-6776 significantly inhibited USP7 at 15µM 108	
(p=0.0503 and 0.0058, respectively; adjusted by the Benjamini-Hochberg False 109	
Discovery Rate method) while remaining selective against 44 to 47 other endogenous 110	
detected deubiquitinases (Fig. 2b, Extended Data Fig. 3c, 3d).  Thus GNE-6640 and 111	
GNE-6776 are highly selective USP7 inhibitors against both recombinant and 112	
endogenous cellular deubiquitinases.  Given these favorable features, we investigated 113	
whether the compounds could be utilized in animal studies.  Pharmacodynamic and 114	
pharmacokinetic studies indicated that GNE-6776 is an orally bioavailable compound 115	
that promotes on-target pathway modulation in human hematologic and solid tumor 116	
xenografts (Supplementary Information Fig. 6a-e).  Although efficacious drug exposure 117	
was only transiently achieved, GNE-6776 caused modest, though significant, EOL-1 118	
xenograft growth delay (Supplementary Information Fig. 6f).  Thus development of USP7 119	
inhibitors having improved drug-like properties will be required in order to demonstrate 120	
the full value of USP7 inhibition in vivo.  121	
 122	
USP7 and MDM2 regulate proteins other than p533,6,11-16 (Fig. 1a).  Having confirmed the 123	
selectivity and on-target cellular potency of GNE-6640 and GNE-6776, we screened 441 124	
cell lines from 15 tumor indications in three-day viability assays to enable an unbiased 125	
analysis of cellular factors that contribute to USP7 inhibitor sensitivity (Extended Data 126	
Fig. 4a).  GNE-6641 was inactive in all cell lines whereas GNE-6640 decreased viability 127	
of 108 cell lines with IC50 ≤10µM (data not shown).  Next, we selected a subset of 181 128	
cell lines from six tumor indications that displayed a range of sensitivities for confirmation 129	
and more extensive analysis (Extended Data Fig. 4a).  GNE-6641 remained inactive in a 130	
five-day viability assay, whereas GNE-6640 and GNE-6776 decreased viability of 54 and 131	
six cell lines, respectively, with IC50 ≤10µM (Extended Data Fig. 4b).  Five-day viability 132	
data and exome sequencing analysis were integrated to identify potential features 133	
associated with compound sensitivity.  Acute myeloid leukemia (AML) cell lines were 134	
significantly associated with increased sensitivity to GNE-6640 (Extended Data Fig. 4c, 135	
4e).			Loss-of-function mutant TP53 lines were in general less responsive than wild-type 136	
TP53 lines, but the trend was not statistically significant (Extended Data Fig. 4d).  137	
Indeed, the TP53 R175 hotspot was associated with increased sensitivity while the Y220 138	
hotspot was associated with decreased sensitivity (Extended Data Fig. 4c, 4e).  To 139	
further investigate the mechanisms by which TP53 status regulates viability in response 140	
to USP7 inhibition, we imaged cellular proliferation and caspase activation in TP53 wild-141	
type and TP53-null cell lines treated with USP7 inhibitors.  Both compounds decreased 142	
proliferation and activated caspases in TP53 wild-type cell lines.  These effects were 143	
reduced, but not abolished, in the evaluated TP53-null cell lines (Extended Data Fig. 5a-144	
5c).  Combining GNE-6640 with doxorubicin or cisplatin, DNA-damaging agents that 145	
activate the p53 response17, enhanced the efficacy of USP7 inhibitors (Extended Data 146	
Fig. 6a, 6b).  Thus immunoblot analysis and cellular viability studies indicate that the 147	
MDM2/p53 pathway is a mediator of GNE-6640 and GNE-6776 cellular activity but is not 148	
the only determinant.  These findings corroborate genetic studies crossing TP53-/- mice 149	
with USP7-/- mice, that afford only a partial rescue of the USP7-/- embryonic lethality7.   150	
 151	
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The enhanced efficacy of GNE-6640 in combination with DNA damaging agents 152	
suggested a strategy to identify cellular signaling pathways that intersect with USP7 153	
inhibition.  We therefore screened the EOL-1 AML cell line using a panel of 589 154	
chemotherapeutic and targeted agents in combination with GNE-6640 or GNE-6776.  155	
Top hits for both compounds included inhibitors of PI3K and PIM kinases (Extended 156	
Data Fig. 6c, 6d, Supplementary Information Table 1). PIM kinases are reported to share 157	
substrates with PI3K pathway kinases including TSC1/2 and the pro-apoptotic Bcl-2 158	
family member Bad (Extended Data Fig. 7d)18.  Given the role of PIM kinases, 159	
particularly PIM2, in hematological malignancies18, we confirmed combination efficacy 160	
with Bliss score analysis using PIM inhibitors GDC-033919 or GDC-0570 (Fig. 2c, 161	
Extended Data Figures 7a-7c).  Both Pim inhibitors share structural similarities and are 162	
highly potent against Pim kinases while remaining selective against other kinases 163	
(manuscripts in preparation).  We also investigated cellular mechanisms of combination 164	
efficacy.  Whereas GNE-6776 promoted a modest elevation of p21 levels in EOL-1 and 165	
MV-4-11 cell lines, PIM2 levels were reduced.  The GNE-6776-induced decrease in 166	
PIM2 protein level was rescued by inhibition of the ubiquitin-activating enzyme UAE1, 167	
that globally blocks ubiquitination of cellular proteins, and the proteasome inhibitor 168	
bortezomib, that inhibits degradation of ubiquitinated proteins.  PIM2 levels were also 169	
lower in USP7 null cells and were rescued by proteasome inhibition, collectively 170	
indicating that USP7 stabilizes PIM2 levels via a ubiquitin/proteasome-dependent 171	
mechanism (Extended Data Fig. 7e, 7f).  Analysis of a treatment time course with GNE-172	
6776, the PIM inhibitor GDC-0570, or the two compounds in combination revealed that, 173	
as expected, GDC-0570 reduced phosphorylation of the S6 ribosomal protein and of 174	
Bad, and decreased expression of short-lived proteins including p21 and the pro-survival 175	
Bcl-2 family member Mcl-1.  GNE-6776 decreased PIM2 levels over time and 176	
remarkably, also reduced S6 and Bad phosphorylation and total Mcl-1 levels, similar to 177	
PIM inhibitor treatment.  In combination, GNE-6776 and GDC-0570 treatments 178	
enhanced the apoptosis indicators cleaved PARP and cleaved caspase-3, confirming 179	
the cell viability combination data (Fig. 2d).  We therefore hypothesized that USP7 180	
regulates PIM2 ubiquitination:  upon USP7 inhibition, ubiquitin modifications accumulate 181	
on PIM2 that promote PIM2 proteasomal degradation.  In support of this idea, 182	
endogenous USP7 associates with PIM2 in cellular lysates and GNE-6776 treatment 183	
enhances PIM2 ubiquitination (Fig. 2e, Extended Data Fig. 7g).  Furthermore 184	
recombinant USP7, but not a C223S catalytic mutant, deubiquitinated PIM2 in vitro 185	
(Extended Data Fig. 7h). Our data thus reveal a previously undescribed juncture 186	
between USP7 deubiquitinase activity and PIM signaling.  This finding expands the 187	
repertoire of USP7-regulated oncogenic signaling pathways beyond MDM2/p53 188	
signaling and merits further investigation in additional cell lines and indications. 189	
 190	
Given the selectivity and efficacy of GNE-6640 and GNE-6776, it was of interest to 191	
understand the precise molecular mechanisms by which these tool compounds inhibit 192	
USP7.  Enzymatic studies utilizing a ubiquitin-AMC substrate verified that the 193	
compounds inhibit intrinsic USP7 catalytic activity (kcat) and notably, attenuate substrate 194	
binding (Km) (Extended Data Fig. 8a).  NMR analysis confirmed that USP7 inhibitors 195	
weaken USP7 interactions with native ubiquitin (Fig. 3a, Extended Data Fig. 8b, 8c).  196	
Analysis of co-crystal structures revealed that both compounds bind into a pocket 197	
approximately 12Å from the catalytic triad that is located at the interface of the palm, 198	
fingers, and thumb sub-domains (Fig. 3b, Extended Data Fig. 7d, 7e). The phenol-199	
aminopyridine moieties of both compounds make similar interactions with their phenol 200	
rings buried in the pocket and hydroxyl groups engaged in H-bond interactions with 201	
H403, which is located at the tip of the b8 sheet. The 2-aminopyridine is directed out of 202	
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the pocket towards solvent with the 2-amino group engaging D349, which is located on 203	
the loop connecting b2 and b3. The two different chemical moieties at the 5-position of 204	
the aminopyridine, namely the pyridine-carboxamide (GNE-6776) and indazole (GNE-205	
6440), are largely solvent exposed and lie between the a5 and a6 helices.  The NH 206	
atoms of the carboxamide of GNE-6776 engages USP7-D305 on the a5 helix and the 207	
indazole of GNE-6640 makes extensive van der Waals contacts in the crevice between 208	
a5 and a6 (Fig. 3c, Extended Data Fig. 7d).  Comparison of the co-crystal structures of 209	
GNE-6776 and GNE-6640 with the USP7-ubiquitin complex structure (PDB 1NBF) 210	
revealed that the compounds likely sterically inhibit ubiquitin binding and prevent the 211	
transition of the USP7 a5 helix to the active conformation5 (Fig. 3c, Extended Data Fig. 212	
7d).  However, given the extensive interactions between USP7 and ubiquitin5, we 213	
investigated the functional significance of residues on the a5 helix of USP7 that interact 214	
with K48 in the USP7-ubiqutin structure.  The K48A mutant of ubiquitin has reduced 215	
affinity for USP7 (Extended Data Fig. 9a).  Similarly, recombinant D305A/E308A USP7 216	
catalytic domain failed to cleave tetra-K48- or tetra-K63-linked polyubiquitin conjugated 217	
to a TAMRA-labeled peptide20 and enzymatic analysis revealed this apparent inactivity 218	
was due to a significantly increased Km of 1120 µM (Extended Data Fig. 9b, 9c).  219	
Importantly, expression of a D305A/E308A USP7 mutant increased K48-linked 220	
polyubiquitination on endogenous MDM2, similarly to expression of catalytically-inactive 221	
USP7 (Extended Data Fig. 9d), thus demonstrating the importance of ubiquitin-K48 and 222	
USP7-D305/E308 residues for USP7/ubiquitin binding and substrate deubiquitination.  223	
 224	
The GNE-6640 and GNE-6776 USP7-interaction modes independently implicated the 225	
ubiquitin-K48 side-chain as a key contributor to USP7 binding, suggesting that USP7 226	
preferentially associates with ubiquitin moieties having free K48 side-chains.  227	
Mechanistically this could direct USP7 to distal subunits of K48-linked polyubiquitin, 228	
resulting in sequential distal-to-proximal chain depolymerization (exo-cleavage).  229	
However in non-K48-linked chains, USP7 may bind and cleave proximal to any ubiquitin 230	
moieties having accessible K48 side-chains (exo-, endo-, or base-cleavage) (Extended 231	
Data Fig. 10a).  In order to evaluate this idea, it was necessary to engineer K48- and 232	
K63-linked di-ubiquitin with differentially-labeled distal and proximal ubiquitin subunits 233	
using spectroscopically distinct amino acids.  To select the ubiquitin residues for isotopic 234	
labeling, we evaluated the chemical shift perturbations induced by USP7 binding 235	
(Extended Data Fig. 10b).  The cluster of residues L8, T12, T14, and L15 broaden upon 236	
USP7 binding and are well-resolved in the spectra, thus Leu residues were isotopically 237	
labeled with 15N in the proximal di-ubiquitin subunit and Thr residues were 15N-labeled in 238	
the distal subunit (Fig. 4a, Extended Data Fig. 10b, 10c).  NMR analysis of these 239	
differentially-labeled di-ubiquitins showed preferential USP7 binding to the distal subunit 240	
of K48-linked di-ubiquitin while USP7 binding was similar to both proximal and distal 241	
K63-linked di-ubiquitin subunits (Fig. 4a, top panels, Extended Data Fig. 10c).  242	
Importantly, both D305A USP7 and D305A/E308A USP7 mutants demonstrated similar 243	
binding to both proximal and distal K48-linked di-ubiquitin subunits (Fig. 4a, bottom 244	
panels).  Based on these data, we evaluated whether differential di-ubiquitin binding 245	
impacts the dynamics of ubiquitin chain depolymerization by USP7.  A previous study 246	
reported that USP7 cleaves K6-, K11-, K33-, K48-, and K63-linked di-ubiquitins with 247	
similar kcat and Km values, indicating that different isopeptide bond conformations do not 248	
significantly impact cleavage efficiency21.  Remarkably, our studies reveal that USP7 249	
sequentially depolymerizes tetra-K48-linked ubiquitin from the distal residue (exo-250	
cleavage) whereas tetra-K63-ubiquitin chains are cleaved via a combination of exo-, 251	
endo-, or base-cleavage, as nearly complete depolymerization occurs within four 252	
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minutes (Fig. 4b, Extended Data Fig. 10d, 10e).  Thus USP7 preferentially binds 253	
ubiquitin moieties that have a free K48 side-chain, resulting in protracted and sequential 254	
depolymerization of K48-linked polyubiquitin.  255	
 256	
Herein we describe the development and characterization of GNE-6640 and GNE-6776, 257	
bona fide USP7 inhibitors having clear selectivity against other deubiquitinases and a 258	
structurally-defined, unique mechanism of action.  Establishing a compound selection 259	
cascade of biochemical, biophysical, and cellular assays using inactive control 260	
compounds for cross-validation was critical for selecting on-target inhibitors and guiding 261	
their optimization.  Additionally, combination studies revealed a previously undescribed 262	
intersection between USP7 deubiquitinase activity and PIM kinases in regulating cell 263	
viability.  Co-crystal structures of GNE-6640 and GNE-6776 demonstrate that both 264	
compounds specifically inhibit USP7 deubiquitinase activity by binding into a unique 265	
pocket at the interface of USP7 palm, fingers, and thumb sub-domains and sterically 266	
block ubiquitin binding.  These inhibitor binding modes also pointed to the potential 267	
importance of the complementary charged interactions between USP7-D305/E308 and 268	
ubiquitin-K48, which we confirmed via mutational analysis.  Notably D305G has been 269	
identified as a somatic loss-of-function mutant in acute lymphoblastic leukemia 270	
patients22.  Furthermore, NMR analysis of USP7 binding to native monoubiquitin and 271	
differentially-labeled di-ubiquitins revealed that USP7 preferentially interacts with 272	
ubiquitin moieties having free K48 side-chains.  Thus, although USP7 cleaves most 273	
ubiquitin-isopeptide linkages non-selectively21, USP7 chain depolymerization is markedly 274	
protracted for K48-linked polyubiquitin relative to K63-linked polyubiquitin.  It has been 275	
proposed that the inefficiency of some deubiquitinases to depolymerize longer substrate-276	
conjugated K48-linked chains enables a threshold for proteasome-targeting 277	
polyubiquitination23; our studies substantiate this idea and provide a biophysical 278	
mechanism.  Numerous proteins including other deubiquitinases, ubiquitin ligases, DNA 279	
repair and endocytosis machinery, and epigenetic regulators are functionally dependent 280	
on ubiquitin binding24.  Developing selective inhibitors that attenuate ubiquitin binding, 281	
instead of directly targeting active-site residues, is an effective strategy for USP7 282	
inhibition.  Our studies demonstrate the feasibility of this approach, that may have 283	
broader applications for inhibiting other classes of ubiquitin-binding proteins. 284	285	
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Figure Legends 376	
 377	
Figure 1:  Identification and characterization of USP7 inhibitors.  a. Schematic of 378	
USP7-regulated signaling.  USP7 inhibition increases substrate ubiquitination, leading to 379	
proteasome-mediated substrate degradation.  Increased ubiquitination and subsequent 380	
degradation of the MDM2 ubiquitin ligase stabilizes the p53 tumor suppressor, resulting 381	
in cell cycle arrest or cell death.  MDM2 is also a p53-target gene. b. A schematic of the 382	
USP7 inhibitor hit-to-lead selection cascade.  See text for more details. c. Left panels:  383	
western blot analysis of MDM2 turnover upon USP7 inhibition.  MCF7 cells were treated 384	
with cycloheximide (CHX) for the indicated times with DMSO vehicle or the indicated 385	
compounds.  See Extended Data Fig. 1b for corresponding USP7, p53, and p21 western 386	
blots.  Right panel:  graph showing actin-normalized MDM2 levels from western blots of 387	
three experiments, error bars indicate SD. d. Analysis of endogenous MDM2 388	
polyubiquitinated with K48-linked chains.  Top panel:  denatured lysates from HCT-116 389	
cells treated for 8 hours with the indicated compounds were immunoprecipitated with a 390	
K48 polyubiquitin linkage-specific antibody and immunocomplexes were western blotted 391	
with an anti-MDM2 antibody.  Western blot analysis of whole cell lysates for the indicated 392	
proteins are shown below.  e. Western blot analysis of p53-pathway proteins in wild-type, 393	
USP7 null, or p53-null HCT116 cells after 24-hour treatment with 15µM of the indicated 394	
USP7 inhibitors or inactive controls.  At least three experimental replicates were 395	
performed for panels c. - e. 396	
 397	
Figure 2:  Selectivity of USP7 inhibitors and mechanism of synergy with PIM 398	
kinase inhibition.  a. An activity heatmap of a panel of deubiquitinases incubated with 399	
USP7 inhibitors.  Deubiquitinases at the indicated concentrations were treated with 400	
10µM of the indicated USP7 inhibitor compounds, incubated with di-ubiquitin substrates, 401	
and analyzed by MALDI-TOF mass spectrometry.  Detection of monoubiquitin was used 402	
to quantitate deubiquitinase activity, shown in a gradient of white (0% inhibition) to dark 403	
red (100% inhibition). b. Volcano plots summarizing activity-based profiling data of 404	
endogenous deubiquitinases treated with USP7 inhibitors.  Benjamini-Hochberg False 405	
Discovery Rate-adjusted p-values are plotted vs. normalized log2 fold change in 406	
deubiquitinase activity in 293T cells treated in experimental triplicates (left graph) or 407	
quadruplicates (right graph) with the indicated USP7 inhibitors compared to the indicated 408	
controls. c. Bliss analysis of 9x9 dose response matrix with PIM inhibitor GDC-0570 and 409	
GNE-6776 in EOL-1 cells.  Left panel:  curve fitted viability values at each dose across 410	
the matrix.  Zero represents no effect whereas 100 indicates complete loss of viability.  411	
Right panel:  the difference in observed versus predicted values using the Bliss 412	
independence model.  Positive values indicate a greater than predicted decrease in 413	
viability. d. Time course study of EOL-1 cells treated with 2µM GNE-6776, 0.02µM GDC-414	
0570, or a combination of the two compounds. Cells were collected at the indicated time 415	
points and the indicated proteins were examined by immunoblotting cell lysates.  ** 416	
indicates uncleaved PARP; * indicates cleaved PARP.  e. Analysis of endogenous PIM2 417	
polyubiquitinated with K48-linked chains.  Top panel:  denatured lysates from EOL-1 418	
cells treated for the indicated times with GNE-6776 were immunoprecipitated with a K48 419	
polyubiquitin linkage-specific antibody and immunocomplexes were western blotted with 420	
an anti-PIM2 antibody.  Western blot analysis of whole cell lysates for the indicated 421	
proteins are shown below.     422	
 423	
Figure 3:  USP7 inhibitors compete with ubiquitin binding to USP7.  a. Overlay of a 424	
region of the 2D 1H/15N transverse relaxation optimized spectroscopy (TROSY) spectrum 425	
of the USP7 catalytic domain (orange) highlighting changes induced by binding of 426	
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ubiquitin in the absence (left, blue) and presence of GNE-6776 (middle, dark grey). The 427	
right panel shows the effect of GNE-6776 on labeled USP7 in the absence of ubiquitin in 428	
light gray. Individual peaks stemming from residues E371 and Q287 are highlighted. 429	
Three experimental replicates were performed. b. Left panel:  crystal structure of USP7 430	
catalytic domain in complex with GNE-6776.  The catalytic domain is shown as an 431	
orange cartoon, the ligand as yellow sticks, and the catalytic triad residues are shown as 432	
green sticks with individual atoms colored following CPK color convention.  Right panel:  433	
GNE-6776 compound structure.  c. Left panel:  depiction of the USP7 catalytic 434	
domain/ubiquitin complex PDB 1NBF (green and cyan cartoons, respectively) with the 435	
K48 residue side chain in ubiquitin and the acidic patch D305 and E308 in USP7 436	
represented as sticks.  Binding interactions are shown as gray dashed lines.  Right 437	
panel: the structure of USP7/GNE-6776 (orange cartoon and residue side chains and 438	
yellow sticks, respectively) and the structure of ubiquitin (cyan) modeled in from PDB 439	
1NBF.  GNE-6776 sterically blocks the binding of ubiquitin and prevents the hydrogen 440	
bond interaction between ubiquitin-K48 and USP7-D305.  The E308 side chain is also 441	
oriented away from ubiquitin-K48.   442	
 443	
Figure 4:  USP7 preferentially binds and cleaves ubiquitin moieties with free K48 444	
side-chains.  a.  Schematic diagrams of differentially labeled di-ubiquitins (also see 445	
Extended Data Fig. 10b, 10c) and representative 2D 1H/15N SOFAST spectra overlays, 446	
and 1D traces extracted from the 1H dimension at the peak maximum.  In both K48- and 447	
K63-linked di-ubiquitin schematics, the distal (dist.) ubiquitin has isotopically-labeled 15N-448	
Thr residues and the proximal (prox.) ubiquitin has 15N-Leu residues, marked with 449	
asterisks.   Top left panel:  K48-linked di-ubiquitin spectra and 1D traces.  Di-ubiquitin 450	
15N-Thr or 15N-Leu peaks are shown in green; the same peaks after addition of unlabeled 451	
USP7-C223A catalytic domain are overlaid in orange.  Top right panel:  K63-linked di-452	
ubiquitin spectra and 1D traces.  Di-ubiquitin 15N-Thr or 15N-Leu peaks are shown in 453	
purple; the same peaks after addition of unlabeled USP7-C223A catalytic domain are 454	
overlaid in orange.  Bottom panels:  the SOFAST experiments with K48-linked di-455	
ubiquitin 15N-Thr or 15N-Leu peaks shown in green and the effect of adding the USP7 456	
catalytic domain double mutant C223A/D305A (left) or triple mutant 457	
C223A/D305A/E308A (right) overlaid in orange. The concentration ratios for the top two 458	
experiments were 1:1 at 70µM ubiquitin, the bottom left was 1:1.5 at 65µM ubiquitin and 459	
the bottom right was 1:2 at 60µM ubiquitin.  b. Time course analysis of peptide-460	
conjugated tetra-ubiquitin chains cleaved by full-length USP7 (above) and corresponding 461	
densitometry plots (below).  Left panels:  time course of USP7-mediated 462	
depolymerization of K48-linked tetra-ubiquitin conjugated to a TAMRA-labeled peptide.  463	
Right panels:  time course of USP7-mediated depolymerization of K63-linked tetra-464	
ubiquitin conjugated to a TAMRA-labeled peptide.  At least three experimental replicates 465	
were performed. 466	
 467	
 468	
 469	
 470	471	
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Extended Data Figure Legends 472	
 473	
Extended Data Figure 1:  Deubiquitinase inhibition and cellular activity of 474	
optimized fragment compounds.   475	
a. A table summarizing deubiquitinase biochemical assay data and ubiquitin-MDM2 476	
assay data from optimized fragment compounds and inactive controls.  Fragment 477	
compound structures are shown below.  b. Western blot analysis of USP7, p53, p21 478	
levels from the cycloheximide (CHX)-chase study of MDM2 turnover shown in Fig. 1c.  479	
c. Analysis of endogenous MDM2 polyubiquitinated with K48-linked chains.  Top panel:  480	
denatured lysates from MCF7 cells treated for 8 hours with the indicated compounds 481	
were immunoprecipitated with a K48 polyubiquitin linkage-specific antibody and 482	
immunocomplexes were western blotted with an anti-MDM2 antibody.  Western blot 483	
analysis of whole cell lysates for the indicated proteins are shown below. d. Cell viability 484	
of wild-type and USP7-null HCT116 colon adenocarcinoma cells, treated as indicated, 485	
and analyzed using the CellTiter-Glo assay.  Data normalized to vehicle control are 486	
plotted as a function of compound concentration.  Two-sided t-tests were used to 487	
calculate p-values between wild-type HCT-116 and USP7-null cells treated with GNE-488	
6640.  7.5µM p = 0.01, 10µM p = 0.041, 12.5µM p = 0.009, 15µM p = 0.011, 20µM p = 489	
0.017.  e.  Cell viability of wild-type and USP7-null HCT116 colon adenocarcinoma cells, 490	
treated and analyzed as in d. with the indicated doses of GNE-6776.  1µM p = 0.023, 491	
2.5µM p = 0.003, 5µM p = 0.001, 7.5µM p = 0.003, 10µM p = 0.007, 12.5µM p = 0.001, 492	
15µM p = 0.007, 17.5µM p = 0.001, 20µM p = 0.008.  At least two experimental 493	
replicates were performed.  494	
 495	
Extended Data Figure 2:  Effects of USP7 inhibitors in human primary cells and 496	
tumor cell lines. 497	
a. Top panels:  representative western blots of p53-pathway proteins and tubulin loading 498	
controls in lysates of tumor cell lines and tissue-matched primary cells after 24 hour 499	
treatment with USP7 inhibitors.  Lower graphs:  bands from p53, p21, and tubulin 500	
immunoblots were quantified and p53 and p21 expression was normalized to tubulin.  501	
The tubulin-normalized p53 or p21 ratio of the DMSO-treated sample in the relevant 502	
primary cell line was arbitrarily set to a value of one.  The average relative ratios of 503	
tubulin-normalized p53 or p21 expression levels are plotted for four (breast cell lines) or 504	
three (osteo-cell lines) biological replicate experiments.  Asterisks indicate p<0.05, two-505	
sided t-test. b. Cell viability of tumor cell lines and tissue-matched primary cells, treated 506	
as indicated, and analyzed using the CellTiter-Glo assay.  Data normalized to vehicle 507	
control are plotted as a function of compound concentration. At least three experimental 508	
replicates were performed for panels a and b.  509	
 510	
Extended Data Figure 3:  Selectivity and cellular efficacy of USP7 inhibitors. 511	
a. GNE-6776 dose-dependent inhibition of di-ubiquitin cleavage by USP7 measured by 512	
MALDI-TOF and plotted using SigmaPlot v.12.5. b. Percent inhibition of the indicated 513	
deubiquitinases for cleaving di-ubiquitins after treatment with 100µM of the indicated 514	
USP7 inhibitor compounds.  Deubiquitinase concentrations and di-ubiquitin substrates 515	
are as in Fig. 2a. c. Supporting western blots for Fig. 2b, left panel.  HEK-293T cell 516	
lysates were treated with the indicated USP7 inhibitors (0.1% DMSO control = 0µM 517	
compound) and endogenous deubiquitinases were reacted with the HA-ubiquitin-518	
vinylsulfone activity-based probe (HA-Ub-VS).  Reacted cell lysates were immunoblotted 519	
with the indicated antibodies.  * indicates unreacted deubiquitinases, ** indicates probe-520	
reacted deubiquitinases, the arrowhead points to a band identified by anti-HA 521	
immunoblotting that runs at the expected molecular weight of USP7 and is diminished in 522	
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lysates treated with GNE-6640. d. Supporting western blots for Fig. 2b, right panel.  523	
HEK-293T cell lysates were treated with the indicated USP7 inhibitors, endogenous 524	
deubiquitinases were reacted with the HA-Ub-VS activity-based probe, and reacted cell 525	
lysates were immunoblotted with the indicated antibodies.  * indicates unreacted 526	
deubiquitinases, ** indicates probe-reacted deubiquitinases.   527	
 528	
Extended Data Figure 4:  Bioinformatics analysis of USP7 inhibitor cell viability 529	
screens. 530	
a. Schematic of the cellular viability assay workflow and bioinformatics analysis.  The six 531	
tumor cell line indications included leukemias, lymphomas, lung carcinomas, and breast, 532	
colon, and prostate adenocarcinomas. b. Histogram of IC50 values of GNE-6640, GNE-533	
6446, and GNE-6641 in 181 cell lines.  Mean viability is calculated as the arithmetic 534	
average of the fitted viabilities at each tested dose of GNE-6640 or GNE-6446 535	
normalized to the mean viability of GNE-6641.  c. Univariate analysis of features 536	
associated with viability differences.  The x-axis represents the fold change (log2) in 537	
normalized mean viability between cell lines present or absent for a given feature.  The 538	
y-axis represents the nominal p-value (-log10 scale).  Features with q-values less than 539	
0.05 and absolute log2 fold change greater than 0.1 are colored in red.  Features with 540	
only absolute log2 fold change greater than 0.1 are colored in gold.  P-values were 541	
determined using the two-sided Student’s t-Test and q-values were determined by 542	
correcting resulting p-values for multiple hypothesis testing using the Benjamini and 543	
Hochberg approach.  The size of each point corresponds to the number of cell lines 544	
present with the feature.  d, e. Boxplots of selected features and their respective 545	
associations with normalized mean viability.  The respective p- and q-values are 546	
indicated below. 547	
Extended Data Figure 5:  Live cell imaging of USP7 inhibitor-treated cells. 548	
Graphs showing cell confluence as a function of time (top rows) and normalized caspase 549	
activity (bottom rows) in cells treated with the indicated USP7 inhibitors.  a. TP53 wild-550	
type or TP53 null HCT116 colon adenocarcinoma cells. b. TP53 wild-type MCF7 or 551	
TP53 null MDA-MB157 breast adenocarcinoma cells. c. TP53 wild-type U2OS cells or 552	
TP53 null SaOS osteosarcoma cells.  At least three experimental replicates were 553	
performed for all experiments. 554	
 555	
Extended Data Figure 6:  Viability of USP7 inhibitor-treated cells in combination 556	
with chemotherapeutic and targeted agents. 557	
Graphs showing cell confluence as a function of time (top rows) and normalized caspase 558	
activity (bottom rows) in cells treated with the indicated USP7 inhibitors and/or 559	
chemotherapeutics. a. MCF7 breast adenocarcinoma cells treated with GNE-6640 or 560	
doxorubicin alone or in combination. b. U2OS osteosarcoma cells treated with GNE-561	
6640 or cisplatin alone or in combination.  At least three experimental replicates were 562	
performed for all experiments. c. A pie chart illustrating the distribution of compound 563	
classes in the Genentech Chemical Genomics Compound library, comprising 589 564	
compounds.  NHR = nuclear hormone receptor, GEF = guanine nucleotide exchange 565	
factor, DNA = DNA damaging agent.  d. Bar plot visualizing the -log10 transformed p-566	
value from the Wilcoxon rank sum test evaluating the enrichment of a given compound 567	
target over all concentrations of USP7 inhibitors vs. DMSO experiments in EOL-1 cells. 568	
Only compound targets with 3 or more compounds in the screen were visualized.  Higher 569	
values indicate synergy with USP7 inhibitors and were followed up by Bliss analysis.  570	
Compounds common to certain signaling pathways including PI3K/PIM, RTK/MAPK, 571	
epigenetic regulation, and DNA damage are color-coded as indicated. 572	
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Extended Data Figure 7:  Mechanism of action studies with USP7 inhibitor and PIM 573	
inhibitor combinations.  a.  Compound structure of GDC-0339.  b. PIM inhibitor 574	
viability curves at different fixed doses of GNE-6676 in EOL-1 cells.  c. Bliss analysis of 575	
9x9 dose response matrix with PIM inhibitor GDC-0339 and GNE-6776 in EOL-1 cells.  576	
Left panel:  curve-fitted viability values at each dose across the matrix.  Zero represents 577	
no effect whereas 100 indicates complete loss of viability.  Right panel:  the difference in 578	
observed versus predicted values using the Bliss independence model.  Positive values 579	
indicate a greater than predicted decrease in viability.  d. A schematic of the PI3K 580	
signaling pathway and regulation by PIM kinases.  PIM and AKT kinases regulate Bad 581	
and TSC1/2 phosphorylation status.  Phospho-proteins highlighted in yellow were 582	
profiled in cellular studies shown in Figure 2d. e.  Immunoblot analysis of cell lysates 583	
from the indicated cell lines treated with GNE-6776 (2µM for 18 hours), a UAE1 inhibitor 584	
MLN-7243 (5µM for 45 minutes) or the proteasome inhibitor bortezomib (5µM for 45 585	
minutes).  f. Immunoblot analysis of cell lysates from the indicated cell lines, either 586	
untreated or treated with the proteasome inhibitor bortezomib (5µM for 45 minutes). g.  587	
Immunoprecipitation of cellular lysates using an anti-USP7 antibody or an isotype-588	
matched control antibody indicates a specific interaction between endogenous USP7 589	
and PIM2. h. Wild-type recombinant USP7, but not a catalytically inactive USP7 mutant, 590	
deubiquitinates endogenous polyubiquitinated PIM2 that was immunoprecipitated from 591	
proteasome inhibitor-treated MV-4-11 cells.  	592	
 593	
Extended Data Figure 8:  Enzymatic analysis and supporting structural biology 594	
data for USP7 inhibitors and USP7. 595	
a. Michaelis-Menten kinetic analysis of USP7 and a series of ubiquitin-AMC substrate 596	
titrations with the indicated USP7 inhibitors. Initial rate of substrate hydrolysis was 597	
determined using the Magellan software on a Tecan Safire2 plate reader and kinetic 598	
parameters were modeled using nonlinear regression analysis with GraphPad Prism 599	
software.  Standard error was calculated from at least 3 experimental replicates. b. 600	
Affinity values of ubiquitin binding to USP7 catalytic domain in the absence and 601	
presence of USP7 inhibitors. The values were determined by titration of unlabeled 602	
ubiquitin to labeled USP7 catalytic domain and the NMR chemical shift changes were 603	
fitted as described in the methods. Standard error was calculated from at least 3 604	
experimental replicates.  c. Overlay of a region of the 2D 1H/15N transverse relaxation 605	
optimized spectroscopy (TROSY) spectrum of the USP7 catalytic domain (orange) 606	
highlighting changes induced by binding of ubiquitin in the absence (left, blue) and 607	
presence of GNE-6640 (right, black).  Individual peaks stemming from residues E371 608	
and Q387 are highlighted. Three experimental replicates were performed. d. 609	
Comparison of the crystal structure of USP7 catalytic domain in complex with GNE-6640 610	
(cyan) and GNE-6776 (yellow). The catalytic domain is shown as an orange cartoon and 611	
the side chains of the residues in proximity to the inhibitor binding sites are shown as 612	
orange sticks.  GNE-6640 and GNE-6776 compound structures are indicated above.  e. 613	
Data collection and refinement statistics for GNE-6440 and GNE-6776 crystal structures 614	
with the USP7 catalytic domain.  615	
 616	
Extended Data Figure 9:  Analysis of the functional significance of the interactions 617	
between ubiquitin-K48 and USP7-D305, -E308 residues. 618	
a. Titration curves showing the effect of unlabeled wild-type ubiquitin (top) and ubiquitin 619	
K48A (bottom) addition to [2H/15N] labeled USP7 catalytic domain.  The weighted 620	
combined 1H/15N chemical shift change is plotted against the ubiquitin concentration for 621	
5 well-resolved peaks stemming from E371, Q387, A381, D342 and Y339 residues in the 622	
15N TROSY spectrum.  Standard error was calculated from at least three experimental 623	
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replicates.  b. Time course analysis of peptide-conjugated tetra-ubiquitin chains reacted 624	
with the USP7 catalytic domain D305A/E308A mutant.  c. Michaelis-Menten analysis of 625	
USP7 catalytic domain D305A/E308A mutant showing the results of three independent 626	
experiments.  d. Evaluation of endogenous MDM2 ubiquitination status upon expression 627	
of wild-type, C223A, or D305A/E308A full-length USP7. Top panel:  denatured lysates 628	
from MCF7 cells transfected with the indicated USP7 expression constructs were 629	
immunoprecipitated with a K48 linkage-specific antibody and immunocomplexes were 630	
blotted with an MDM2 antibody.  Western blot analysis of whole cell lysates for the 631	
indicated proteins are shown below.  Three experimental replicates were performed.  632	
 633	
Extended Data Figure 10:  Analysis of differential USP7 binding to K48- and K63-634	
linked poly-ubiquitin and depolymerization kinetics. 635	
a. Schematic diagrams of substrate-bound K48-linked polyubiquitin chains (left) and 636	
K63-linked chains (right), and proposed USP7 interactions.  Dashed lines indicate 637	
residue side-chains and the • symbol indicates an isopeptide bond between the ubiquitin 638	
C-terminus and a Lys residue side chain.  The proximal ubiquitin subunits (ligated to the 639	
substrate) and their K48 or K63 side-chains are indicated with “a” subscripts, the next 640	
most distal ubiquitin subunits and side-chains are indicated with “b” subscripts, etc.  641	
Preferential USP7 binding to free K48 side-chains would direct USP7 to the distal 642	
ubiquitin subunit of K48 polyubiquitin and promote sequential exo-cleavage, whereas 643	
USP7 would bind all subunits of K63-polyubiquitin and promote exo-, endo-, and base-644	
cleavage.  b. The 1H/15N SOFAST spectrum of labeled ubiquitin (cyan), superimposed 645	
with the spectrum of a 1:1 molar ration of labeled ubiquitin in the presence of unlabeled 646	
USP7-catalytic domain (orange).  Ubiquitin residues affected by the USP7 interaction, 647	
that results in exchange broadening of the residue cross peaks, are labeled with grey or 648	
blue text and correspond to the residues depicted in Extended Data Fig. 10c.  The K48 649	
and K63 residues are labeled with red font; the L43 and L50 residues labeled with green 650	
font do not broaden upon USP7 binding and serve as internal controls.  The box 651	
highlights the region depicted in Fig. 4a. c. Structure depictions by ribbon diagrams of 652	
the covalent complex between USP7 catalytic domain (orange) with ubiquitin (cyan); 653	
(PDB code 1NBF) [top panel], K48 linked di-ubiquitin (green; PDB code 2KDE) [lower left 654	
panel], and K63 linked di-ubiquitin (purple; PDB code 2RR9) [lower right panel].  In all 655	
diagrams, highlighted spheres are the residues in ubiquitin that are broadened in the 656	
1H/15N SOFAST spectrum of 1H/15N labeled protein by addition of unlabeled USP7 657	
catalytic domain (see Extended Data Fig. 10b for more details).  Leu or Thr residues 658	
colored in blue show well-resolved peaks and were amenable to selective 15N labeling of 659	
di-ubiquitin, highlighted with asterisks in the corresponding schematic diagrams.  Lysine 660	
side chains of K48 and K63 are indicated as sticks in red. d. Time course analysis of 661	
peptide-conjugated tetra-ubiquitin chains cleaved by the USP7 catalytic domain (above) 662	
and corresponding densitometry plots (below).  Left panels:  time course of USP7 663	
catalytic domain-mediated depolymerization of K48-linked tetra-ubiquitin conjugated to a 664	
TAMRA-labeled peptide.  Right panels:  time course of USP7 catalytic domain-mediated 665	
depolymerization of K63-linked tetra-ubiquitin conjugated to a TAMRA-labeled peptide.  666	
e. A shorter 0 – 7 minute time-course analysis of TAMRA peptide-K63 tetra-ubiquitin 667	
conjugate depolymerization by full-length USP7 (top gel) and the corresponding 668	
densitometry plot (below).  At least three experimental replicates were performed.669	
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Supplementary Information figure legends and summary 670	
 671	
Supplementary Information Figure 1:  Screening cascades for USP7 inhibitors. 672	
a.  High-throughput activity-based screening cascade to identify USP7 673	
inhibitors.  Screening stages are identified in bold print.  Numbers of compounds at each 674	
stage are provided to the right of each box.  Criteria for progression to the next stage are 675	
highlighted in italics to the left of each arrow.  b.  Confirmed hits from USP7 676	
screen.  Structures and assay results are provided for 5 of the 101 confirmed 677	
actives.  The compounds were clustered by structural similarity.  IC50 values and Hill 678	
slopes were determined from 10-point dose titrations with n=2.  c.  Fragment NMR 679	
screen diagram.  Screening stages are identified in bold print.  Numbers of compounds 680	
at each stage are provided to the right of each box.  Criteria for progression to the next 681	
stage are highlighted in italics to the left of each arrow.  Protein Saturation Transfer 682	
Difference (STD) experiments were performed at 283K.  Primary USP7 catalytic domain 683	
binders were selected based on the signal to noise (S/N) of the respective compound 684	
with a cut-off of greater than 5. All primary binders were re-measured as single 685	
compounds under otherwise identical conditions and confirmed binders selected having 686	
a S/N of greater than 10.  Hits were further tested for specific binding to USP7 catalytic 687	
domain by measurement of 1H15N TROSY protein spectra.  Positive hits were defined as 688	
compounds that induced chemical shift perturbations.  Perturbations were classified by 689	
the chemical shift patterns and selected compounds passed onto X-ray soaking 690	
experiments.   691	
 692	
Supplementary Information Figure 2:  Hit-to-lead selection assay data summary 693	
for lead USP7 inhibitors. 694	
A table summarizing the hit-to-lead assay results of the lead compounds identified by the 695	
high throughput screening and NMR fragment screening campaigns.  Compound series 696	
are grouped in columns and hit-to-lead selection assay data are listed in the indicated 697	
rows.  See Fig. 1b and text for more details.    698	
 699	
Indole tricyclic compounds including GNE-8735 increased total MDM2 levels and 700	
inhibited cathepsin-B, indicating poor selectivity and induction of general cell stress by 701	
this chemical series (see also Supplementary Information Fig. 3a and 3b).  Indole 702	
tricyclics also precipitated caspase-3, although they passed dynamic light scattering 703	
(DLS) analysis (see also Supplementary Information Fig. 4a).  The peptidomimetic 704	
compounds had weaker biochemical potency, poor selectivity, and covalently modified 705	
USP7 cysteine (Cys) residues other than the catalytic Cys (data not shown).  Given 706	
these data, and because optimization of indole tricyclic and peptidomimetic compounds 707	
proved challenging, these series were discontinued.  The tetrahydroacridine and 708	
fragment compounds were relatively potent, selective, and enhanced cellular MDM2 709	
ubiquitination without significantly increasing total MDM2 (see also Supplementary Fig. 710	
3a and 3b).  Tetrahydroacridine compounds passed cathepsin-B inhibition assays, 711	
demonstrating additional protease selectivity.  Neither tetrahydroacridine nor fragment 712	
compounds showed evidence of USP7 aggregation in DLS or in NMR studies (see 713	
Supplementary Fig. 4a and data not shown). Tetrahydroacridine compounds, including 714	
GNE-6831, covalently modified USP7, consistent with a previous report describing a 715	
similar series25 (see also Supplementary Information Fig. 4b).  716	
 717	
 718	
 719	
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Supplementary Information Figure 3:  Analysis of total- and ubiquitin-MDM2 levels 720	
in cells. 721	
a. Cellular MDM2 immunofluorescence studies.  HCT-116 human colorectal carcinoma 722	
cells were treated with a range of concentrations of the indicated USP7 inhibitors or 723	
DMSO vehicle for 24 hours and endogenous MDM2 protein levels were detected by 724	
immunofluorescence imaging.  Depicted images show cells treated with 10 µM of the 725	
indicated compounds or DMSO vehicle control. The graph shows the quantified mean 726	
nuclear MDM2 protein levels per cell over a range of concentrations of GNE-8735 and 727	
GNE-2916 (error bars represent standard deviation). The half maximal effective 728	
concentration (EC50) for the elevation in MDM2 caused by GNE-8735 was 2.9 µM. b. 729	
Quantitation of total- and ubiquitinated-MDM2 (Ub-MDM2) in USP7 inhibitor-treated 730	
cells.  SJSA-1 human osteosarcoma cells were treated with a range of concentrations of 731	
the indicated USP7 inhibitors or DMSO vehicle control for 24 hours and the level of 732	
ubiquitinated-MDM2 and total MDM2 were measured using a multiplexed Mesoscale 733	
immunoassay.  Representative graphs show the quantified level of either total MDM2 734	
(right column, red), ubiquitinated MDM2 (central column, blue) or the ratio of the 735	
ubiquitinated-MDM2 signal and the total MDM2 signal (left column, orange). All data are 736	
shown as percentage change in each value, relative to DMSO vehicle-treated samples. 737	
The maximal extent of the increase in the ubiquitinated-MDM2/total MDM2 ratio varied 738	
between compounds and in most cases did not reach a plateau. In order to compare the 739	
potency of the on the increase in the ratio of ubiquitinated-MDM2/total MDM2 between 740	
compounds, the top level was set to 100% and was universally applied to calculate a 741	
value for the half maximal effective concentration (EC50) of the percent change in this 742	
ratio relative to DMSO (shown in the left column).  At least two experimental replicates 743	
were performed. 744	
 745	
Supplementary Information Figure 4:  Biophysical analysis of selected USP7 746	
inhibitors. 747	
a. The DLS autocorrelation functions are shown for 100µM Rottlerin (red), full-length 748	
USP7 with 100µM GNE-8735 (blue), full-length USP7 with 100µM GNE-2090 (brown) 749	
and full-length USP7 with 0.1% DMSO vehicle control (black). The percent aggregate by 750	
mass is shown in the table. b. USP7 full-length protein was incubated overnight with 751	
excess of GNE-6831 and analyzed by LC-MS. Unmodified and covalently modified 752	
USP7 are represented in the top and bottom panels, respectively.  Three experimental 753	
replicates were performed. 754	
  	755	
Supplementary Information Figure 5:  Deubiquitinase inhibition, ubiquitin-MDM2, 756	
and cellular viability data for tetrahydroacridine and fragment compounds. 757	
a. A table of active and inactive tetrahydroacridine compounds with structures.  Hit-to-758	
lead selection assay data are listed in the indicated rows.  See Fig. 1b and text for more 759	
details. b. A table of active and inactive fragment compounds with structures.  Hit-to-lead 760	
selection assay data are listed in the indicated rows.  See Fig. 1b and text for more 761	
details. c. Cell viability assays in AMO-1 cells treated as indicated with the 762	
tetrahydroacridine compounds (top graph; purple lines are inactive controls and the 763	
green line is the active compound) and fragment compounds (bottom graph; red lines 764	
are inactive controls and the blue line is the active compound).  Data normalized to 765	
vehicle control are plotted as a function of compound concentration. d. Cell viability 766	
assays in KMS12-PE cells treated as indicated with the tetrahydroacridine compounds 767	
(top graph; purple lines are inactive controls and the green line is the active compound) 768	
and fragment compounds (bottom graph; red lines are inactive controls and the blue line 769	
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is the active compound).  Data normalized to vehicle control are plotted as a function of 770	
compound concentration.  At least two experimental replicates were performed.   771	
 772	
Tetrahydroacridine compounds GNE-6831 and GNE-2090 decreased viability of KMS12-773	
PE and AMO1 multiple myeloma cell lines but this activity was not differentiated from 774	
control compounds GNE-0956, -2143 and -2148.  In contrast, the fragment compound 775	
GNE-2916 decreased multiple myeloma cell viability significantly more than control 776	
compounds GNE-2917, -2931, and -9603.  Thus work on tetrahydroacridine series was 777	
discontinued and we focused on optimizing the fragment series. 778	
 779	
Supplementary Information Figure 6: in vitro and in vivo drug metabolism and 780	
pharmacokinetic (DMPK) profiling, pharmacodynamic effects, and xenograft 781	
growth inhibition studies with GNE-6776. 782	
a. In vitro pharmacokinetic assessment of USP7 inhibitors.  Calculated drug properties 783	
are indicated:  molecular weight (MW), lipophilicity at pH 7.4 (LogD7.4), total polar surface 784	
area (tPSA), stability in hepatic microsomes (LM CLhep) or hepatocytes (Hep CLhep) from 785	
human/rat/mouse/dog/cyno (h/r/m/d/c) species, percent plasma protein binding (PPB %) 786	
and permeability across an MDCK cell monolayer from basolateral to apical (B to A) or 787	
apical to basolateral (A to B) directions. b. EOL-1 cell line viability in response to GNE-788	
6776 as measured in a five-day CellTiterGlo assay performed in triplicate. c. In vivo 789	
pharmacokinetic analysis of GNE-6776.  Mice (3 per group) were dosed PO with 100 790	
mg/kg or 200 mg/kg of GNE-6776.  Plasma concentrations of GNE-6776 were measured 791	
at the indicated time points and plotted as a function of time.  Exposure metrics relating 792	
to the free fraction EC50 for EOL-1 cells are also indicated, where target exposure = 793	
(EOL-1 IC50)/(1 - %PPB) = 1.54µM/0.066 = 23.33µM. d. Western blot analysis of MCF7-794	
Ser xenografted tumors.  Mice harboring MCF7-Ser xenograft tumors were treated with 795	
vehicle or 200 mg/kg GNE-6776 at 0 and 4 hours; 8 hours after the initial treatment 796	
tumors were excised and the indicated proteins were examined by immunoblotting tumor 797	
lysates. e. Pharmacodynamic analysis of USP7 inhibitor-treated EOL-1 xenografted 798	
tumors.  Mice growing EOL-1 xenograft tumors were dosed by mouth with vehicle or 200 799	
mg/kg GNE-6776 at 0 and 4 hours; 8 hours after the initial treatment tumors were 800	
excised and the indicated proteins were examined by immunoblotting tumor lysates. f.  801	
EOL-1 xenograft growth inhibition study of mice treated PO with vehicle or the indicated 802	
doses of GNE-6776.  n = 7 mice per group, p-values were calculated using Dunnett’s 803	
multiple comparison test.  Asterisks indicate significant growth inhibition relative to 804	
vehicle-treated mice.  Day 4 100 mg/kg p = 0.0163, Day 4 200 mg/kg p = 0.0138, Day 6 805	
200 mg/kg p = 0.0344.   806	
 807	
Supplementary Table 1 808	
This table summarizes the results of the compound library combination screen 809	
performed in EOL-1 cells in the presence of either DMSO or varying concentrations of 810	
GNE-6776 or GNE-6640.  Column headers denote compound used and concentration 811	
used (ie. 1000nM_6776 indicates 1000 nM of GNE-6776 treatment in combination with 812	
each compound).  For each compound treatment, two summary statistics are listed that 813	
are derived from 9-point dose response curves:  IC50 is the determined IC50 value of 814	
the dose response curve.  This is set to the highest concentration applied if no IC50 was 815	
attained.  Mean viability is the mean over all 9 dose viability measures.  For each non-816	
DMSO treatment two values are calculated to indicate synergy between the library 817	
compound and the USP7 inhibitor tested:  mvdiff indicates the difference in mean 818	
viability between the DMSO treatment and the USP7 inhibitor.  Positive values indicate a 819	
lower viability in the USP7-treated condition, which indicates synergism.  Log2fc 820	
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indicates the log2 ratio between the IC50 value of the DMSO treatment and the USP7 821	
treatment.  Negative values indicate lower IC50s for the USP7 treatment, also signaling 822	
synergism.  All unique compounds are assigned an internal gcgcid (Genentech Chemical 823	
Genomics Compound ID) for tracking purposes.  Common drug names are shown in the 824	
compound_name column and either protein or functional targets of the compound, 825	
where known, are listed in the target_name column. 826	827	
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Methods 828	
 829	
High-throughput screen (HTS) and counterscreen assays 830	
USP7 UbA10 TR-FRET activity assay.  Potential inhibitors of USP7 were identified in a 831	
TR-FRET-based enzyme activity assay with UbA10 as substrate.  UbA10 is a fragment 832	
of the naturally occurring ubiquitin precursor, Ub52; it retains the 10 amino acid segment 833	
of Ub52 that extends beyond the ubiquitin C-terminus.  The primary screening assay is a 834	
novel TR-FRET based activity assay that measures cleavage by full-length USP7 of a 835	
doubly-tagged peptide substrate.  The peptide is tagged with GST on the N-terminus 836	
and with eight histidine residues on the C-terminus (GST-UbA10-His).  The tags are 837	
detected by anti-GSH-d2 (TR-FRET acceptor) and anti-His-europium (TR-FRET donor), 838	
respectively.  Cleavage of this substrate by USP7 at the ubiquitin C-terminus results in 839	
separation of these two tags and loss of TR-FRET signal.  Compounds were dispensed 840	
into 1536-well black plates (MaKO, Aurora Microplates, Whitefish, MT) followed by 2µL 841	
full-length recombinant USP7 in assay buffer (50 mM HEPES pH 7.5, 0.1% Prionex 842	
[Pentapharm, Basel, CH], 0.01% Triton X-100, and 10 mM DTT).  After a 10-minute 843	
incubation, the reaction was started by the addition of 2µL GST-UbA10-His substrate in 844	
assay buffer.  After 75 minutes of reaction, 2µL of a detection antibody reagent, 845	
containing anti-His-europium (Life Technologies, Carlsbad, CA) and anti-GST-d2 846	
(CISbio, Bedford, MA) in assay buffer were added.  After 60 minutes, the fluorescence at 847	
618 nm and 671 nm with excitation at 340 nm was read on a ViewLux reader 848	
(PerkinElmer, Waltham, MA).  Cleavage of the doubly-tagged substrate resulted in loss 849	
of TR-FRET signal, while inhibition of USP7 by compound restored the signal.  The TR-850	
FRET ratio was calculated as fluorescence at 671 nm/ fluorescence at 618 nm.  TR-851	
FRET ratios were normalized to controls to determine percent inhibition for the single 852	
concentration screen.  For confirmation in concentration-response mode (10 points with 853	
N = 2), percent inhibition was plotted against compound concentration, and the data 854	
were fit to a 4-parameter curve with Screener Assay Analyzer (Genedata, Basel, CH) to 855	
determine IC50 values.  The assay buffer was optimized to maintain enzyme stability and 856	
to maximize assay signal to background:  Triton X-100 was included to prevent 857	
nonspecific adsorption of the enzyme and/or substrate to the assay plate and/or to 858	
compound aggregates, Prionex carrier protein was included to help stabilize the enzyme 859	
and to prevent nonspecific adsorption to container and tubing surfaces as well as to 860	
minimize nonspecific inhibition by library compounds, and DTT served to maintain good 861	
USP7 activity and minimize the impact of inhibitors that act through redox cycling.  862	
Reagent concentrations were optimized for good assay performance at approximately 863	
50% substrate conversion in the signal decrease assay with a key aim of minimizing the 864	
required concentration of USP7.  The GST-UbA10-His concentration was adjusted to 865	
maximize assay signal, anti-GST-d2 concentration was adjusted approximately in 866	
parallel with that of the substrate, and anti-His-europium was used at a concentration 867	
that represented a minimum that is compatible with robust detection on the ViewLux 868	
plate reader.  Time course evaluations were conducted to confirm that the enzyme 869	
concentration (10 nM) and reaction time (75 minutes) were in the linear range of enzyme 870	
activity.  Additionally, extended time courses for the detection reaction were used to 871	
demonstrate that the 60-minute incubation was sufficient to reach equilibrium.  Under the 872	
final assay conditions, reagent stability studies indicated greater than 20 hours of 873	
acceptable performance.  Over the course of the screen, Z’ values averaged 0.76. 874	
 875	
USP7 di-ubiquitin FRET activity assay.  Potential USP7 inhibitors were confirmed in an 876	
orthogonal activity assay with an internally quenched K63-linked di-ubiquitin substrate 877	
(U-310, Boston Biochem, Cambridge, MA).  Conditions were similar to those used for the 878	
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UbA10 TR-FRET activity assay.  Compounds dispensed into 1536-well plates were 879	
preincubated with full-length recombinant USP7 in assay buffer for 10 minutes, and the 880	
reaction was started by the addition of 2µL of the di-ubiquitin substrate.  During the 60-881	
minute incubation, cleavage of the substrate by USP7 resulted in the release of 882	
quenching of the TAMRA tag by the QXL tag and thus an increase in fluorescence.  The 883	
fluorescence intensity was read with excitation at 540 nm and emission at 585 nm.  884	
Concentration-response assay methods and data analyses were conducted as for the 885	
UbA10 TR-FRET assay.  886	
 887	
USP7 Ubiquitin/Rho110 activity assay.  Potential USP7 inhibitors were also confirmed in 888	
an orthogonal activity assay with ubiquitin/rhodamine-110 as substrate.  Compounds 889	
were preincubated for 10 minutes with 2µL full-length recombinant USP7 in assay buffer, 890	
and the reaction was started by the addition of 2µL of ubiquitin/rhodamine-110 (U-555, 891	
Boston Biochem).  After a 60-minute reaction in which USP7 cleaves the rhodamine-110 892	
from the ubiquitin and thus increases fluorescence, the fluorescence intensity was read 893	
with excitation at 485 nm and emission at 535 nm.  General assay conditions and data 894	
analyses were as described above. 895	
 896	
USP7 di-ubiquitin cleavage assay with mass spectrometric detection.  To further validate 897	
compounds that met the initial HTS confirmation criteria, the ability of compounds to 898	
inhibit di-ubiquitin cleavage was assessed by monitoring the conversion to ubiquitin by 899	
mass spectrometry.  Compounds were dispensed into 384-well polypropylene plates 900	
(Greiner Bio-One, Kremsmunster, AT), and 10μL USP7 were added and allowed to 901	
incubate for 10 minutes.  The reaction was started by the addition of 10μL of K48-linked 902	
di-ubiquitin substrate (UC-200, Boston Biochem) and allowed to progress for 70 minutes; 903	
then it was stopped by addition of 20μL 2% formic acid.  The assay plates were stored 904	
frozen at -80 °C until analysis by mass spectrometry at Agilent Technologies (Wakefield, 905	
MA).  Prior to quantitation, the enzyme reaction was passed over a RapidFire cartridge 906	
to remove buffer components.  Both di-ubiquitin substrate consumption and ubiquitin 907	
product formation were monitored by mass spectrometry using multiple reaction 908	
monitoring (MRM) in positive ion mode with parent ion/daughter ion transitions of 909	
1142.1/260.1 and 770.8/817.7, respectively.  Percent conversion of substrate was 910	
plotted as a function of compound concentration to generate the IC50 values as indicated 911	
above.  912	
 913	
NMR screen and binding studies 914	
All NMR spectra were recorded on Bruker Avance-600 and 800 MHz spectrometers 915	
operating at 14.1 and 18.8 Tesla using triple resonance cryogenic probes optimized for 916	
proton detection. All two-dimensional spectra were acquired with a spectral width of 16 917	
ppm and 2048 (TROSY) or 954 (SOFAST) data points in the direct proton dimension 918	
and 28 ppm and 192 sample points in the 15N dimension with echo-antiecho (TROSY) or 919	
States-TPPI (SOFAST)  type selection. The resulting free induction decay resolution was 920	
12.52 and 19.05 Hz point for the TROSY and 20.08 and 17.10 Hz/data point for the 921	
SOFAST spectra respectively. All spectra were recorded at 300 K. The pH was adjusted 922	
to 7.2 without correction due to isotope shifts.  For data processing NMRPipe/NMRDraw 923	
and the BRUKER software package TOPSPIN 3.2 were used. All data evaluation was 924	
done in NMR view and CCPN. Visualization and presentation of the 3D tertiary USP7-as 925	
well as related protein structures from the RSCB Protein Database was done in Pymol 926	
(The PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC). The 927	
sequential assignment of USP7 has been deposited in the Biological Magnetic 928	
Resonance Bank and can be retrieved with the accession number 26766.  All samples 929	
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contained 137 mM NaCl, 10 mM Na2HPO4, 27 mM KCl and 1.8 mM KH2PO4 adjusted to 930	
a pH of 7.2 and contained 7% (w/w) 2H2O and 0.5 μM NaN3. Ubiquitin titration 931	
experiments were done by addition of purified bovine ubiquitin (from erythrocytes, 932	
Sigma) from a stock solution of 20mM in the same buffer. All proton chemical shifts were 933	
referenced to internal DSS (50 μM) and 15N referenced indirectly using the 1H chemical 934	
shift of the methyl group in DSS by multiplication with a factor of 0.101329118. 935	
 936	
NMR screening conditions.  The primary fragment screen was performed on 4871 937	
fragments in mixtures of 5. The individual compound concentration was 500µM, the 938	
concentration of unlabeled USP7-CD was 7µM. Binders were identified by the presence 939	
of signals stemming from the individual ligand in the proton saturation transfer difference 940	
spectra recorded at 284K. The criterion used to identify a binder was a signal to noise 941	
ratio above 5. All primary binders were re-measured as a single compound to confirm 942	
binding. Confirmed binders were defined as compounds with an STD signal to noise 943	
ratio above 10. All confirmed binders were tested again, at 2-2.5mM, by protein 944	
observed 1H/15N TROSY experiments in the presence of 15N USP7-CD at 220-340uM.  945	
 946	
NMR binding studies.  The concentration-dependent NMR shift perturbations caused by 947	
the interaction of unlabeled ubiquitin with labeled USP7 catalytic domain in the absence 948	
and presence of USP7 inhibitors were fit to the function for a two state fast exchanging 949	
equilibrium: 950	
(∆𝛿 = ∆𝛿$%& '() * ) + , ('() * ) + )/	,1[*][+]4[*] ) where Dd is the chemical shift change at 951	
various protein/ligand ratios, Ddmax is the chemical shift change at saturation, Kd  is the 952	
dissociation constant, and [L] and [P] are the ligand and protein concentrations, 953	
respectively. The chemical shift change is the root mean square of the 1H and 15N values 954	
scaled by 1 and 0.15 respectively. Seven ubiquitin concentrations were measured (0, 955	
100, 250, 500, 750, 1000, 2500uM). USP7 inhibitors were added at 1mM. The mean 956	
values and standard deviation were calculated by averaging the values obtained for 957	
eight well-resolved cross peaks:  Y339, S341, D342, G375, A381, G382, D412, and 958	
I419. Data were visualized using GraphPad Prism.  959	
 960	
Compound synthesis 961	
Synthesis of GNE-6640 is representative of the syntheses for GNE-6776, GNE-6641, 962	
GNE-2931, GNE-2917, and GNE-2916 . 963	
3,5-Dibromo-4-ethylpyridin-2-amine:  Into a 500-mL 3-necked round-bottom flask 964	
purged and maintained with an inert atmosphere of nitrogen was placed 4-ethylpyridin-2-965	
amine (10 g, 81.85 mM), tetrahydrofuran (200 mL), and NBS (29 g, 162.94 mmol) at 0 966	
oC. The resulting solution was stirred at room temperature for 15 min and then 967	
concentrated under vacuum. The residue was purified on a silica gel column eluting with 968	
DCM/MeOH (100:1-20:1) to afford 18 g (79%) of the title compound.  1H NMR (400 MHz, 969	
CDCl3) δ 8.04 (s, 1H), 7.33 – 7.23 (m, 0H), 4.93 (s, 2H), 2.93 (q, J = 7.5 Hz, 2H), 1.60 (s, 970	
0H), 1.17 (t, J = 7.5 Hz, 3H).  LCMS (ESI M/Z): 264.1 (M + H+).   971	
3-Bromo-4-ethylpyridin-2-amine:  Into a 500-mL 3-necked round-bottom flask purged 972	
and maintained with an inert atmosphere of nitrogen was placed 3,5-dibromo-4-973	
ethylpyridin-2-amine (18 g, 64.29 mmol) in tetrahydrofuran (300 mL). To this was added 974	
a solution of n-BuLi (in hexane) (58 mL, 2.2 mol/L) at -78 oC. The resulting solution was 975	
stirred at -78oC for 1 h, quenched by the addition of 450 mL NH4Cl and then extracted 976	
with ethyl acetate (2 x 500 mL). The combined organic layers were washed with brine (2 977	
x 500 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The 978	
crude product was purified by Flash-Prep-HPLC to afford 12 g (93%) of the title 979	
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compound as a white solid.  1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 5.1 Hz, 1H), 6.60 – 980	
6.48 (m, 1H), 4.93 (s, 2H), 2.69 (q, J = 7.6 Hz, 2H), 1.33 – 1.14 (m, 5H).  LCMS (ESI 981	
M/Z): 264.1 (M + H+).   982	
4-Ethyl-3-(4methoxyphenyl)pyridn-2-amine:  Into a 500-mL 3-necked round-bottom 983	
flask purged and maintained with an inert atmosphere of nitrogen was placed a solution 984	
of 3-bromo-4-ethylpyridin-2-amine (12 g, 59.68 mmol) in CH3CN (100 mL), (4-985	
methoxyphenyl)boronic acid (11 g, 72.39 mmol), Na2CO3(120 mL, sat.), and Pd(dppf)Cl2 986	
(1.2 g, 1.64 mmol). The resulting solution was stirred at 110 oC for 1 h, diluted with of 987	
500 mL of EA and then extracted with of ethyl acetate (2 x 500 mL). The combined 988	
organic layers were washed with brine (3 x 200 mL), dried over anhydrous sodium 989	
sulfate and concentrated under vacuum. The residue was purified on a silica gel column 990	
eluting with ethyl acetate/petroleum ether (1:100-1:10) to afford 10 g (73%) of the title 991	
compound. 1H NMR (400 MHz, CDCl3) δ 8.06(d, J = 5.1 Hz, 1H), 7.21 – 7.11 (m, 2H), 992	
7.06 – 6.97 (m, 2H), 6.64 (d, J = 5.4 Hz, 1H), 4.48 (s, 2H), 3.86 (s, 3H), 2.31 (q, J = 7.6 993	
Hz, 2H), 1.11 – 0.88 (m, 3H).  LCMS (ESI M/Z): 264.1 (M + H+).   994	
5-Bromo-4-ethyl-3-(4-methoxyphenyl)pyridin-2-amine:  Into a 250-mL 3-necked 995	
round-bottom flask purged and maintained with an inert atmosphere of nitrogen was 996	
placed 4-ethyl-3-(4methoxyphenyl)pyridn-2-amine (10 g, 43.80 mmol), THF (100 mL), 997	
followed by NBS (7.8 g, 43.83 mmol) at 0 oC. The resulting solution was stirred at room 998	
temperature for 15 min, diluted with 500 mL EtOAc and 500 mL H2O.  The resulting 999	
solution was extracted with  ethyl acetate (2 x 500 mL). The organic layers were 1000	
combined, washed with brine (2 x 500 mL) and concentrated under vacuum. The residue 1001	
was purified on a silica gel column eluting with ethyl acetate/petroleum ether (1:20-1:10) 1002	
to afford 8 g (59%) of the title compound.  1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.22 1003	
– 7.09 (m, 2H), 7.09 – 6.98 (m, 2H), 4.55 (s, 2H), 2.47 (q, J = 7.5 Hz, 2H), 1.10 – 0.84 1004	
(m, 3H).  LCMS (ESI M/Z): 264.1 (M + H+).   1005	
4-(2-Amino-5-bromo-4-ethylpyridin-3-yl)phenol:  Into a 250-mL 3-necked round-1006	
bottom flask purged and maintained with an inert atmosphere of nitrogen was placed 5-1007	
bromo-4-ethyl-3-(4-methoxyphenyl)pyridin-2-amine as a white solid (8 g, 26.04 mmol), 1008	
dichloromethane (100 mL), followed by tribromoborane (19.6 g, 78.24 mmol) at 0 oC. 1009	
The resulting solution was stirred at room temperature for 1 h and then quenched by the 1010	
addition of 100 mL of NaHCO3 (1 M) at 0 oC. The solids were collected by filtration and 1011	
then washed with 100 mL H2O and 300 mL of EA/PE (1:1) to afford 6.3 g (83%) of the 1012	
title compound as a white solid.  1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.22 – 7.09 1013	
(m, 2H), 7.09 – 6.98 (m, 2H), 4.55 (s, 2H), 2.47 (q, J = 7.5 Hz, 2H), 1.10 – 0.84 (m, 3H).  1014	
LCMS (ESI M/Z): 264.1 (M + H+).   1015	
4-[2-Amino-4-ethyl-5-(1H-indazol-5-yl)-3-pyridyl]phenol (GNE-6640):  Into a 250-mL 1016	
3-necked round-bottom flask purged and maintained with an inert atmosphere of 1017	
nitrogen was placed 4-(2-amino-5-bromo-4-ethylpyridin-3-yl)phenol (1.0 g, 3.41 mmol,), 1018	
6-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (880 mg, 3.41 mmol,), potassium 1019	
carbonate (3.3 g, 23.88 mmol), water (30 mL), 1,4-dioxane (25 mL), and Pd(dppf)Cl2 1020	
(200 mg, 0.3 mmol). The resulting solution was stirred at 80 oC for 16 h, diluted with 500 1021	
mL H2O and 500 mL ethyl acetate. The organic layer was washed 30 with brine (2 x 250 1022	
mL) and concentrated under vacuum. The residue was purified on a silica gel column 1023	
eluting with DCM/CH3OH (20:1-10:1) to afford the titled compound. 1H NMR (400 MHz, 1024	
DMSO-d6) δ 13.07 (s, 1H), 9.52 (s, 1H), 8.07 (d, J = 1.0 Hz, 1H), 7.74 (s, 1H), 7.65 (dd, J 1025	
= 1.6, 0.8 Hz, 1H), 7.56 (dt, J = 8.6, 0.9 Hz, 1H), 7.28 (dd, J = 8.5, 1.6 Hz, 1H), 7.10 – 1026	
7.04 (m, 2H), 6.92 – 6.86 (m, 2H), 4.94 (s, 2H), 2.26 (q, J = 7.4 Hz, 2H), 0.60 (t, J = 7.4 1027	
Hz, 3H).  LCMS (ESI M/Z): 331.1 (M+H).  HRMS m/e 331.1533. (M + H+, C20H19ON4  1028	
requires 331.1653) 1029	
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5-[6-Amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridyl]-N-methyl-pyridine-2-1030	
carboxamide (GNE-6776):   1H NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 8.80 (q, J = 1031	
4.7 Hz, 1H), 8.59 (dd, J = 2.3, 0.9 Hz, 1H), 8.07 (dd, J = 8.0, 0.9 Hz, 1H), 7.96 (dd, J = 1032	
8.0, 2.2 Hz, 1H), 7.79 (s, 1H), 7.11 – 7.02 (m, 2H), 6.94 – 6.86 (m, 2H), 5.19 (s, 2H), 1033	
2.84 (d, J = 4.8 Hz, 3H), 2.26 (q, J = 7.4 Hz, 2H), 0.62 (t, J = 7.4 Hz, 3H).  HRMS m/e 1034	
349.1659. (M + H+, C20H21O2N4 requires 349.1650) 1035	
4-[2-Amino-4-ethyl-5-(2-methylindazol-6-yl)-3-pyridyl]phenol (GNE-6641). 1HNMR 1036	
(400MHz, DMSO-d6) δ 9.54 (s, 1H), 7.81 (dd, J = 7.3, 1.5Hz, 2H), 7.77 – 7.52 (m, 4H), 1037	
7.13 – 7.01 (m, 2H), 6.93 – 6.85 (m, 2H), 5.10 (s, 2H), 3.28 (s, 2H), 2.24 (q, J = 7.4Hz, 1038	
2H), 0.60 (t, J = 7.5Hz, 3H).  HRMS m/e 345.1710. (M + H+, C21H21ON4 = 345.1650) 1039	
4-[2-Amino-4-ethyl-5-(2-methoxyphenyl)-3-pyridyl]phenol (GNE-2931). 1H NMR (400 1040	
MHz, DMSO-d6) δ 9.54 (s, 1H), 8.00 (s, 2H), 7.90 – 7.77 (m, 3H), 7.73 (s, 1H), 7.54 – 1041	
7.40 (m, 2H), 7.39 – 7.34 (m, 1H), 7.12 – 7.00 (m, 2H), 6.94 – 6.82 (m, 2H), 3.03 (s, 3H), 1042	
2.91 (q, J = 4.4 Hz, 2H), 1.71 (t, J = 4.4 Hz, 3H).  HRMS m/e 321.1598 (M + H+, 1043	
C20H21O2N2 requires 321.1650) 1044	
3-[6-Amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridyl]benzamide (GNE-2917).  1H NMR 1045	
(400 MHz, DMSO-d6) δ 9.52 (s, 1H), 8.48 (s, 2H), 7.58 (s, 1H), 7.34 (ddd, J = 8.2, 7.3, 1046	
1.8 Hz, 1H), 7.13 (dd, J = 7.4, 1.8 Hz, 1H), 7.10 – 6.94 (m, 6H), 6.88 (d, J = 7.6 Hz, 2H), 1047	
2.91 (q, J = 4.4 Hz, 2H), 1.71 (t, J = 4.4 Hz, 3H).  HRMS m/e 334.1550 (M + H+, 1048	
C20H20O2N3 requires 334.1700) 1049	
4-[6-Amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridyl]benzamide (GNE-2916).  1H NMR 1050	
(400 MHz, DMSO-d6) δ 9.53 (s, 1H), 7.97 (s, 1H), 7.95 – 7.87 (m, 1H), 7.72 (s, 3H), 7.43 1051	
– 7.35 (m, 1H), 7.33 (s, 1H), 7.12 – 7.00 (m, 2H), 6.93 – 6.83 (m, 2H), 5.04 (s, 2H), 2.27 1052	
(q, J = 7.4 Hz, 2H), 0.61 (t, J = 7.5 Hz, 3H).  LCMS (ESI) m/z 334.2 [M+H+] 1053	
Synthesis of GNE-6831 is representative of the syntheses for GNE-2090, GNE-2143, 1054	
and GNE-2148. 1055	
Synthesis of 9-chloro-N-(5-chloro-2,4-dimethoxy-phenyl)-N-(cyanomethyl)-5,6,7,8-1056	
tetrahydroacridine-3-carboxamide (GNE-6831).  9-chloro-5,6,7,8-tetrahydroacridine-3-1057	
carboxylic acid ( 100 mg, 0.38 mmol) was dissolved in 2 mL of DMF and charged with 1058	
HATU (144 mg, 0.38 mmol).  After stirring at RT for minutes, the mixture was then 1059	
charged with 3-((5-chloro-2,4-dimethoxyphenyl)amino)propanenitrile ( 91 mg, 0.38 1060	
mmol).  The resulting solution was stirred at 110 oC for 1 h, diluted with of 50 mL of EA 1061	
and then extracted with ethyl acetate (2 x 100 mL). The combined organic layers were 1062	
washed with brine (3 x 200 mL), dried over anhydrous sodium sulfate and concentrated 1063	
under vacuum. The residue was purified on a silica gel column eluting with ethyl 1064	
acetate/petroleum ether (1:100-1:10) to afford the title compound (110 mg, 0.30 mmol, 1065	
78% yield) of the title compound. 1H NMR (400 MHz, DMSO-d6) δ 8.02 (d, J = 8.7 Hz, 1066	
1H), 7.82 (d, J = 1.7 Hz, 1H), 7.65 – 7.56 (m, 2H), 6.67 (s, 1H), 4.84 (s, 2H), 3.79 (s, 1067	
3H), 3.73 (s, 3H), 2.92 (m, 4H), 1.85 (m, 4H). HRMS m/e 470.1033 (M + H+, 1068	
C24H22O3N3Cl2, requires 470.1029) 1069	
9-Chloro-N-(5-chloro-2,4-dimethoxy-phenyl)-N-(2,3-dihydroxypropyl)-5,6,7,8-1070	
tetrahydroacridine-3-carboxamide (GNE-2090):  1H NMR (400 MHz, DMSO-d6) δ 7.96 1071	
(dd, J = 8.6, 3.4 Hz, 2H), 7.77 – 7.68 (m, 2H), 7.66 – 7.47 (m, 1H), 6.56 (d, J = 14.2 Hz, 1072	
1H), 4.99 (d, J = 5.2 Hz, 1H), 4.54 (tt, J = 15.4, 5.8 Hz, 2H), 3.46 – 3.33 (m, 4H), 2.91 1073	
(m, 4H), 1.85 (m, 4H).  LCMS (ESI) m/z 505.2 [M + H+]. 1074	
9-Chloro-N-(2-hydroxyethyl)-N-methyl-5,6,7,8-tetrahydroacridine-3-carboxamide 1075	
(GNE-2143):  1H NMR (400 MHz, DMSO-d6) δ 8.16 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 8.2 1076	
Hz, 1H), 7.7 (m, 1H), (3.66 (s, 3H), 3.57 (s, 1H), 1.90 (td, J = 3.8, 1.8 Hz, 4H).  HRMS 1077	
m/e 319.1208(M + H+, C17H20O2N2Cl requires 319.1500) 1078	
9-Chloro-N-methyl-N-(2-morpholino-2-oxo-ethyl)-5,6,7,8-tetrahydroacridine-3-1079	
carboxamide (GNE-2148):  1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 8.6 Hz, 1H), 1080	
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8.16 (d, J = 8.6 Hz, 1H), 7.96 – 7.90 (m, 1H), 4.40 (s, 1H), 3.62 (s, 4H), 3.54 – 3.41 (m, 1081	
4H), 3.15 (s, 3H), 3.00 (t, 20.9 Hz, 4H), 1.94 – 1.86 (m, 4H).  HRMS m/e 402.1579 (M + 1082	
H+, C21H25O3N3Cl requires 402.1725) 1083	
 1084	
Synthesis of (1S)-1-(5-bromo-1H-indol-2-yl)-N-(2-phenylethyl)ethanamine (GNE-1085	
0300).  1-(5-bromo-1H-indol-2-yl)ethan-1-one (90 mg, 0.38 mmol) was dissolved in 2 mL 1086	
of DMF and charged with (S)-phenethylamine (46 mg, 0.38 mmol).  After stirring at RT 1087	
for 30 minutes, the mixture was diluted with 50 mL ethyl acetate and 50 mL water.  The 1088	
mixture was partitioned and the organic was collected.  The aqueous was then extracted 1089	
with of ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine 1090	
(3 x 200 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The 1091	
residue was purified on a silica gel column eluting with ethyl acetate/petroleum ether 1092	
(1:100-1:10) to afford the title compound (120 mg, 0.35 mmol, 92% yield) of the titled 1093	
compound. 1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.30 1094	
– 7.19 (m, 3H), 7.20 – 7.06 (m, 4H), 6.21 (d, J = 1.8 Hz, 2H), 3.93 (q, J = 6.6 Hz, 1H), 1095	
2.77 – 2.56 (m, 4H), 1.36 (d, J = 6.6 Hz, 3H). LCMS (ESI) m/z 343.9 [M + H+] 1096	
 1097	
Synthesis of GDC-0570 follows similar procedures as described for GDC-0339 as below. 1098	
(Z)-2,3,6,7-Tetrahydro-1H-azepine hydrochloride: 4N Hydrogen chloride in 1,4-1099	
dioxane (250 mL; 1 mol) was added over 5 minutes to a stirred, ice cooled solution of 1100	
(Z)-tert-butyl 2,3,6,7-tetrahydro-1H-azepine-1-carboxylate (50 g; 0.254 mol) in methanol 1101	
(250 mL).  On complete addition, the ice bath was removed and stirring continued at 1102	
room temperature for 3.75 h.  Volatiles were removed under reduced pressure and the 1103	
residue triturated twice with diethyl ether (300 mL) to afford (Z)-2,3,6,7-tetrahydro-1H-1104	
azepine hydrochloride as a pale pink solid (32.3 g; 95%).  1H-NMR (DMSO-d6, 400 MHz) 1105	
δ 9.54 (br s, 2H), 6.40-6.25 (m, 2H), 3.15-3.05 (m, 4H), 2.55-2.40 (m, 4H).  1106	
 1107	
(Z)-1-(1-Methyl-4-nitro-1H-pyrazol-5-yl)-2,3,6,7-tetrahydro-1H-azepine: A mixture of 1108	
(Z)-2,3,6,7-tetrahydro-1H-azepine hydrochloride (32.3 g; 0.24 mol), 5-chloro-1-methyl-4-1109	
nitro-1H-pyrazole (37.2 g; 0.23 mol), potassium fluoride (56.24 g; 0.96 mol) and 1110	
diisopropylethylamine (64 mL; 0.362 mol) in anhydrous DMSO (650 mL) was heated at 1111	
75 °C  for 21 h.  On cooling, the mixture was poured into water (1500 mL), extracted with 1112	
ethyl acetate (4 x 500 mL) and the combined organics washed with water (2 x 400 mL), 1113	
brine (300 mL) and dried (MgSO4).  The solvent was removed under reduced pressure 1114	
to afford (Z)-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)-2,3,6,7-tetrahydro-1H-azepine as a light 1115	
brown solid (50.74 g; 99%).  1H-NMR (CDCl3, 400 MHz) δ 8.00 (s, 1H), 5.95-5.85 (m, 1116	
2H), 3.80 (s, 3H), 3.30-3.20 (m, 4H), 2.45-2.35 (m, 4H). LCMS (ESI M/Z): 223.1 [M + 1117	
H+].  1118	
 1119	
4-(1-Methyl-4-nitro-1H-pyrazol-5-yl)-8-oxa-4-azabicyclo[5.1.0]octane: 77% meta-1120	
Chloroperbenzoic acid (77 g; 0.343 mol) was added portion-wise over 10 minutes to a 1121	
stirred, ice cooled solution of (Z)-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)-2,3,6,7-tetrahydro-1122	
1H-azepine (50.74 g; 0.23 mol) in dichloromethane (1000 mL).  Ice bath used to control 1123	
minor exotherm observed during a smaller scale reaction.  On complete addition, the ice 1124	
bath was removed and stirring continued at room temperature for 18 h.  The reaction 1125	
mixture was washed with saturated sodium hydrogen carbonate (750 mL), 1N sodium 1126	
hydroxide (2 x 500 mL) and brine (350 mL).  The organics were dried (MgSO4) and the 1127	
solvent removed under reduced pressure to afford 4-(1-methyl-4-nitro-1H-pyrazol-5-yl)-1128	
8-oxa-4-azabicyclo[5.1.0]octane as a pale yellow solid (55.6 g).  1H-NMR (CDCl3, 400 1129	
MHz) δ 7.98 (s, 1H), 3.75 (s, 3H), 3.50-3.35 (m, 2H), 3.30-3.20 (m, 2H), 2.95-2.80 (m, 1130	
2H), 2.35-2.15 (m, 4H). LCMS (ESI M/Z): 239.2 [M + H+]. 1131	
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 1132	
rel-(4R,5R)-5-Azido-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-ol: To a stirred 1133	
solution of 4-(1-methyl-4-nitro-1H-pyrazol-5-yl)-8-oxa-4-azabicyclo[5.1.0]octane (29.28 g) 1134	
in methanol (350 mL) and water (90 mL) was added ammonium chloride (16.5 g; 0.308 1135	
mol) followed by sodium azide (20 g; 0.307 mol).  The mixture was heated behind a blast 1136	
screen at 70 °C for 22 h, cooled then concentrated to 100 mL under reduced pressure at 1137	
40 °C.  The concentrated solution was poured into water (1300 mL), extracted with 1138	
dichloromethane (4 x 400 mL) and the combined organics dried (MgSO4).  Evaporation 1139	
under reduced pressure at 35 °C gave rel-(4R,5R)-5-azido-1-(1-methyl-4-nitro-1H-1140	
pyrazol-5-yl)azepan-4-ol (anti-isomer and a racemic mixture) as a pale yellow oil (34.5 g; 1141	
96% over 2 steps).  1H-NMR (CDCl3, 400 MHz) δ 8.03 (s, 1H), 3.85-3.77 (m, 1H), 3.77 1142	
(s, 3H), 3.65-3.55 (m, 1H), 3.45-3.15 (m, 4H), 2.85-2.70 (m, 1H), 2.25-2.10 (m, 2H), 1143	
2.05-1.85 (m, 2H). LCMS (ESI M/Z): 282.1 [M + H+]. 1144	
 1145	
rel-(4R,5R)-4-Azido-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepane: 50% 1146	
Deoxofluor in THF (111 mL; 0.307 mol) was added slowly over 20 minutes to a stirred, 1147	
ice cooled solution of rel-(4R,5R)-5-azido-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-1148	
ol (32.5 g; 0.115 mol) in dichloromethane (500 mL).  On complete addition, the ice bath 1149	
was removed and stirring continued at room temperature for 20 h.  The reaction mixture 1150	
was re-cooled in an ice bath and saturated sodium hydrogen carbonate (400 mL) added 1151	
dropwise (effervescence!).  After stirring for 30 minutes the layers were separated and 1152	
the aqueous layer extracted with dichloromethane (2 x 500 mL).  Pooled organics were 1153	
dried (MgSO4) and the solvent removed under reduced pressure.  Flash column 1154	
chromatography on silica eluting with 0 – 100% ethyl acetate in isohexane gradient 1155	
afforded rel-(4R,5R)-4-azido-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepane as a 1156	
pale orange oil (26 g; 80%).  1H-NMR (CDCl3, 400 MHz) δ 8.03 (s, 1H), 4.90-4.65 (m, 1157	
1H), 4.00-3.85 (m, 1H), 3.77 (s, 3H), 3.40-3.10 (m, 4H), 2.35-2.05 (m, 3H), 1.95-1.75 (m, 1158	
1H). LCMS (ESI M/Z): 284.3 [M + H+]. 1159	
 1160	
rel-(4R,5R)-5-Fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-amine: A mixture 1161	
of rel-(4R,5R)-4-azido-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepane (26 g; 91.8 1162	
mmol) and triphenylphosphine (24.1 g; 92 mmol) in tetrahydrofuran (400 mL) and water 1163	
(80 mL) was heated at 60 °C for 20 h, cooled and concentrated to approximate 80 mL 1164	
under reduced pressure.  Ethyl acetate (500 mL) was added and the mixture extracted 1165	
with 1N HCl (4 x 125 mL).  Pooled acidic extracts were washed with ethyl acetate (500 1166	
mL), basified to pH 14 with 6N NaOH and extracted with dichloromethane (3 x 400 mL).  1167	
Combined extracts were dried (MgSO4) and the solvent removed under reduced 1168	
pressure to give rel-(4R,5R)-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-amine 1169	
as a pale yellow oil (22 g; 93%).  1H-NMR (CDCl3, 400 MHz) δ 8.03 (s, 1H), 4.60-4.40 1170	
(m, 1H), 3.77 (s, 3H), 3.45-3.10 (m, 5H), 2.35-1.90 (m, 3H), 1.80-1.65 (m, 1H), 1.60 (br 1171	
s, 2H). LCMS (ESI M/Z): 258.3 [M + H+]. 1172	
 1173	
tert-Butyl (4R,5R)-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-1174	
ylcarbamate: Di-tert-butyl dicarbonate (28 g; 128.3 mmol) was added to a stirred, ice 1175	
cooled solution of rel-(4R,5R)-5-fluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-1176	
amine (22 g; 85.6 mmol) and diisopropylethylamine (22.4 mL; 128.6 mmol) in 1177	
dichloromethane (600 mL).  On complete addition, the ice bath was removed and stirring 1178	
continued at room temperature for 20 h.  The reaction mixture was washed with 1179	
saturated sodium hydrogen carbonate (500 mL) and the aqueous layer re-extracted with 1180	
dichloromethane (2 x 300 mL).  Pooled organics were dried (MgSO4) and the solvent 1181	
removed under reduced pressure.  Flash column chromatography on silica eluting with 0 1182	
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– 100% ethyl acetate in isohexane gradient afforded a pale yellow solid (29.7 g; 97%).  1183	
Chiral separation of the racemic mixture by supercritical fluid chromatography (SFC) 1184	
using Chiralpak IA column with an isocratic mobile phase of 15% methanol (with 0.1% 1185	
NH4OH) in carbon dioxide gave the desired product (second peak) as a single 1186	
enantiomer. 1H-NMR (CDCl3, 400 MHz) δ 8.04 (s, 1H), 5.05 (m, 1H), 4.80-4.55 (m, 1H), 1187	
4.15-4.05 (m, 1H), 3.79 (s, 3H), 3.45-3.10 (m, 4H), 2.35-2.05 (m, 3H), 1.95-1.80 (m, 1H), 1188	
1.47 ( s, 9H). LCMS (ESI M/Z): 358.3 [M + H+]. 1189	
 1190	
tert-Butyl (4R,5R)-5-fluoro-1-(4-amino-1-methyl-1H-pyrazol-5-yl)azepan-4-1191	
ylcarbamate: To a stirred solution of tert-butyl (4R,5R)-5-fluoro-1-(1-methyl-4-nitro-1H-1192	
pyrazol-5-yl)azepan-4-ylcarbamate (15.0 g; 42 mmol) in ethanol (1000 mL) and water 1193	
(100 mL) was added ammonium chloride (11.34 g; 210 mmol) and iron powder (9.4 g; 1194	
168 mmol).  The mixture was heated at 99 °C for 2.75 h, cooled, filtered through Celite® 1195	
and evaporated to approximately 100 mL.  The concentrate was diluted with water (1000 1196	
mL) and extracted with ethyl acetate (2 x 500 mL).  The pooled extracts were washed 1197	
with water (200 mL), dried (MgSO4) and the solvent removed under reduced pressure to 1198	
give tert-butyl (4R,5R)-5-fluoro-1-(4-amino-1-methyl-1H-pyrazol-5-yl)azepan-4-1199	
ylcarbamate as a pale brown solid (12.6 g; 91%).  1H-NMR (CDCl3, 400MHz) δ 7.13 (s, 1200	
1H), 6.35-6.20 (m, 1H), 4.85-4.65 (m, 1H), 4.35-4.15 (m, 1H), 3.66 (s, 3H), 3.45-3.30 (m, 1201	
2H), 3.15-2.90 (m, 2H), 2.65 (s, 2H), 2.30-2.15 (m, 1H), 2.15-1.95 (m, 2H), 1.90-1.80 (m, 1202	
1H), 1.45 (s, 9H). LCMS (ESI M/Z): 327.2 [M + H+]. 1203	
 1204	
tert-Butyl (4R,5R)-1-(4-(5-tert-butoxycarbonylamino-2-(2,6-difluorophenyl)thiazole-1205	
4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-5-fluoroazepan-4-ylcarbamate: A mixture 1206	
of tert-butyl (4R,5R)-5-fluoro-1-(4-amino-1-methyl-1H-pyrazol-5-yl)azepan-4-ylcarbamate 1207	
(12.6 g, 38.5 mmol), 5-(tert-butoxycarbonylamino)-2-(2,6-difluorophenyl)thiazole-4-1208	
carboxylic acid (14.4 g, 40.4 mmol), diisopropylethylamine (13.4 mL, 77 mmol) and 1209	
PyBOP (26.1 g, 50 mmol) in dichloromethane (400 mL) was stirred at room temperature 1210	
for 48 h.  Saturated sodium hydrogen carbonate (600 mL) was added and stirring 1211	
continued for 0.5 h.  The mixture was filtered, the layers separated and the aqueous 1212	
extracted with dichloromethane (500 mL).  The pooled organics were dried (MgSO4) and 1213	
the solvent removed under reduced pressure.  Flash column chromatography on silica 1214	
eluting with 0 – 100% ethyl acetate in isohexane gradient afforded tert-butyl (4R,5R)-1-1215	
(4-(5-tert-butoxycarbonylamino-2-(2,6-difluorophenyl)thiazole-4-carboxamido)-1-methyl-1216	
1H-pyrazol-5-yl)-5-fluoroazepan-4-ylcarbamate as a pale yellow solid (2.5 g, 9.8%).  1217	
Further elution with 0-10% methanol in ethyl acetate, then 10% methanol in 1218	
dichloromethane, evaporation of relevant fractions under reduced pressure and 1219	
trituration of the residue with cold diethyl ether gave a further 7.61g (30%) of product. 1H-1220	
NMR (CDCl3, 400MHz) δ 10.34 (s, 1H), 8.75 (s, 1H), 7.89 (s, 1H), 7.40-7.25 (m, 1H), 1221	
7.15-7.00 (m, 2H), 4.95-4.85 (m, 1H),4.85-4.65 (m, 1H), 4.15-4.00 (m, 1H), 3.77 (s, 3H), 1222	
3.45-3.30 (m, 2H), 3.25-3.00 (m, 2H), 2.35-2.10 (m, 3H), 1.95-1.75 (m, 1H), 1.55 (s, 9H), 1223	
1.43 (s, 9H).  1224	
 1225	
5-Amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-1226	
(2,6-difluorophenyl)thiazole-4-carboxamide (GDC-0339): tert-butyl (4R,5R)-1-(4-(5-1227	
tert-butoxycarbonylamino-2-(2,6-difluorophenyl)thiazole-4-carboxamido)-1-methyl-1H-1228	
pyrazol-5-yl)-5-fluoroazepan-4-ylcarbamate (10.11 g, 15.2 mmol) in 4N HCl in dioxane 1229	
(200 mL) and methanol (200 mL) was stirred at room temperature for 20 h.  Evaporation 1230	
under reduced pressure afforded a pale brown solid which was dissolved in 50% 1231	
methanol in dichloromethane and added to an SCX cartridge (strong cation exchange 1232	
chromatography).  After washing with dichloromethane and methanol, elution with 1N 1233	
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ammonia in methanol and evaporation of the eluent under reduced pressure afforded 5-1234	
amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-1235	
difluorophenyl)thiazole-4-carboxamide as the free base (6.3 g, 89%).  1H-NMR (DMSO-1236	
d6, 400MHz) δ 8.92 (s, 1H), 7.65-7.50 (m, 4H), 7.40-7.25 (m, 2H), 4.60-4.45 (m, 1H), 1237	
3.70 (s, 3H), 3.35-3.05 (m, 5H), 2.30-1.60 (m, 6H).  LCMS (ESI M/Z): 466.1 [M + H+]. 1238	
 1239	
Hit-to-lead selection cascade assays 1240	
Biochemical deubiquitinase assays.  Biochemical deubiquitinase assays used Ubiquitin-1241	
Rho110 as a substrate to enable kinetic monitoring of reactions for USP7, USP7 1242	
catalytic domain, USP5, and USP47. The deubiquitinase proteins and their 1243	
concentrations that were used in biochemical reactions were as follows:  USP7, full-1244	
length N-terminal His-tag, native C-Terminus: 0.18 nM (Genentech, Hs_USP7 2-1102); 1245	
USP7 catalytic domain N-terminal His-tag: 40 nM (Genentech, Hs_USP7.K208-K554); 1246	
USP5; full-length: 0.5 nM (Boston Biochem cat # E-322, lot 02010210); USP47, full-1247	
length N-terminal His-tag:0.8 nM (Genentech Hs_USP47.M1-D1287). Substrate Km 1248	
values for USP proteins were: USP7, full-length, 2 µM; USP5, full-length, 0.33 µM; 1249	
USP47 full-length, 0.175 µM. The final assay conditions were as follows: The Reaction 1250	
Buffer consisted of 50 mM Tris (pH 7.5), 0.01%(v/v) Triton X-100, 2.5 mM Dithiothreitol, 1251	
0.1% (w/v) bovine gamma globulin (Sigma cat # G5009-25G). The final substrate 1252	
Ubiquitin-Rho110 (Boston Biochem cat # U-555) concentration used for reactions was 1253	
1µM. Reactions were carried out for 1 hour at room temperature, in black 20µL volume 1254	
polystyrene ProxiPlate 384 F Plus (PerkinElmer cat # 6008260). Test compounds, 1255	
including a control USP7 inhibitor (Ub-aldehyde, Boston Biochem cat # U-201) were 1256	
serially diluted in DMSO, in 384-well clear V-bottom polypropylene plates (Greiner cat # 1257	
781280). Compounds in DMSO were diluted 10-fold into Reaction Buffer, to achieve 3-1258	
fold the final desired concentration. The substrate, Ubiquitin-Rho110 (Boston Biochem 1259	
cat # U-555), was prepared at 3µM (3-fold the final concentration) and 5µL was 1260	
dispensed into the reaction plate.  Five µL of the compounds (diluted in Reaction Buffer 1261	
at 3-fold the final concentration) were transferred to the reaction plate.  Five µL of DUB 1262	
protein, which was diluted in Reaction Buffer at 3-fold the final concentration, was 1263	
transferred to the reaction plate to initiate the reaction. After 1 hour incubation at room 1264	
temperature the reaction was quenched by the addition of 5µL of 400mM acetic acid, in 1265	
the case of an endpoint reaction. The enzymatic product was measured by quantifying 1266	
the fluorescence signal of cleaved Rhodamine-110 using excitation at 485 nm and 1267	
emission at 535nm. When pre-incubation of DUB with compounds was required, the 1268	
order of addition of reagents was modified to pre-mix the compounds with DUB (with a 1 1269	
hour incubation period), prior to the addition of the substrate and the initiation of the 1270	
reaction period. Percentage inhibition values were calculated relative to a no enzyme 1271	
control and an uninhibited enzyme control. Curve fitting and IC50 calculations were 1272	
carried out using Genedata Screener software. Conversion between IC50 and Ki values 1273	
were carried out using the Cheng-Prusoff equation. 1274	
 1275	
Cellular ubiquitin-MDM2 assay.  HCT116 colon cancer cells or SJSA-1 osteosarcoma 1276	
cells were seeded at a density of 150,000 cell per well in 90µl (RPMI 1640 media, 10% 1277	
FBS (or 0.5% FBS for low serum conditions), 1X GlutaMAX™ from Gibco) in 96-well 1278	
black clear bottom, TC-treated (Greiner, Cat# 655090), and incubated for 2 hours at 1279	
37°C, 5% CO2 in a tissue culture incubator. Compounds were prepared in a serial 1280	
dilution in DMSO at 200x the final desired concentration in a 96-well polypropylene V-1281	
bottom (Greiner, Cat# 651261), then diluted 1:20 in RPMI tissue culture medium and 1282	
10µl transferred to each well of the cell plate. Cell plates were incubated overnight for 20 1283	
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hours, 37°C, 5% CO2.  Twenty µl of a 120 µM stock (in RPMI) of the proteasome 1284	
inhibitor, MG132 (Cayman Chemical, Cat# 10012628), was added to each well. Cells 1285	
were incubated for 1 hour at 37°C, 5% CO2. Quantitation of ubiquitin-MDM2 was carried 1286	
out using Ub/Total MDM2 whole cell lysate kit (MSD, Cat# K15168D-2). Cells were lysed 1287	
by adding 15µl of 5x MSD lysis buffer (containing additives: 10mM NaF, 10mM beta-1288	
glycerophosphate, 1.5mM Na3VO4, protease inhibitor cocktail (Sigma, P8340) to each 1289	
well and incubated at 4°C for 30 minutes with shaking.  One hundred µl of lysate was 1290	
transferred to each well of the MSD 96-well plate, incubated at room temperature for 1 1291	
hour while shaking (650 RPM) in the dark. The MSD plates were washed 3 times in Tris 1292	
buffered saline (50 mM Tris-Cl, pH 7.5. 150 mM NaCl) using a Biotek EL405 plate 1293	
washer.  Three mL of detection antibody solution was prepared per plate (1 mL of block 1294	
buffer A, 1.82ml 1X Tris wash buffer, 150µl 2% Blocker D-M, 30µl 10% Blocker D-R, 1295	
60µl 50X anti-total MDM2 antibody).  Twenty-five µl of detection antibody solution was 1296	
added per well and incubated for 1 hour at room temperature (650RPM) in the dark. 1297	
Plates were washed 3 times in Tris buffered saline using a Biotek EL405 plate washer.  1298	
MSD read buffer was prepared according to manufacturer’s instructions and 150 µl 1299	
added per well. Plates were read using a MSD Sector Reader. The final measurement 1300	
was the ratio of ubiquitinated MDM2 / total MDM2.  Percentage increase in ubiquitin-1301	
MDM2 was calculated relative to DMSO controls using Genedata Screener software.  1302	
 1303	
Total MDM2 immunofluorescence.  HCT-116 cells were seeded at a density of 1304	
40,000/well in 50µL/well in 384 well tissue culture plates (Greiner #781091) in RPMI, 1305	
10% FBS, 2mM L-glutamine, and incubated overnight. Test compounds were prepared 1306	
in a 20-point serial dilution (1:2-fold) in DMSO using a Biomek FX in a 384 well Labcyte-1307	
approved polypropylene plate (Labcyte P05525). Compounds were acoustically 1308	
dispensed into the cell plates using a Labcyte Echo (final total volume transferred was 1309	
50nL (DMSO final concentration was 0.1%v/v). Cell plates were incubated at 37°C 5% 1310	
CO2, for 24 hours. Cells were fixed by addition of 15µL of 16% paraformaldehyde 1311	
(Electron Microscopy Sciences #15710-S) directly to the 50µL cell culture medium in 1312	
each well. Plates were incubated for 30 minutes at room temperature. The well contents 1313	
was aspirated using the Biotek EL406 and 50µL/well of Permeabilization / Block buffer 1314	
added (Phosphate buffered saline (PBS, pH 7.5), Triton X100 0.5% (v/v), BSA 0.5% 1315	
(w/v), proclin 15ppm). Plates were incubated for 30 minutes then washed 3 times with 1316	
100µL/well of PBS. Twenty-five µL/well of anti-MDM2 (rabbit polyclonal, AbCam 1317	
#ab58530 diluted 1:500 in PBS, BSA 0.5% (w/v), Triton X100 0.1% (v/v)) was dispensed 1318	
into each well. Plates were incubated 2 hours at room temperature then washed 4 times 1319	
with 100uL/well of PBS using a Biotek EL406. Twenty-five µL/well of Alexafluor 555 1320	
conjugated anti-rabbit IgG (Life Technologies #A31572, diluted 1:1000 and Hoechst 1321	
33342 1µg/mL diluted in PBS, BSA 0.5% (w/v), Triton X100 0.1% (v/v)) was dispensed 1322	
into each well. Plates were incubated for 2 hours at room temperature then washed 4 1323	
times with 100µL/well of PBS using a Biotek EL406.  Fluorescence images of the 1324	
samples (Channel 1: 386-23_BGRFRN_ BGRFRN (DNA); Channel 2: 549-1325	
15_BGRFRN_ BGRFRN (MDM2)) were acquired using a Cellomics XTI Arrayscan with 1326	
the Bioapplication “Compartmental Analysis”. Channel 1 was used to define the nuclear 1327	
region. Measurements were made of “Mean_CircAvgIntCh2”, which is the Alexafluor 555 1328	
fluorescence intensity (MDM2) within the nuclear region measured on a per cell basis 1329	
and averaged over all the measured cells. Data analysis and EC50 calculation was 1330	
carried out in GraphPad Prism using non-linear four parameter curve fitting. 1331	
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Cathepsin-B protease assay.  Cathepsin-B proteolytic activity is quantitated by an 1333	
LC/MS, MRM-based detection method.  Briefly, varying concentrations of experimental 1334	
compound are incubated with 0.5 nM human liver Cathepsin-B (EMD Millipore, #219364) 1335	
and Benzyloxycarbonyl-Arg-Arg-7-amino-4-methylcoumarin (Cbz-RR-AMC) fluorogenic 1336	
substrate in buffer containing 10 mM MES pH 6.0 and 1 mM DTT.  The reaction is 1337	
incubated for 5 minutes at room temperature, followed by quenching with the addition of 1338	
an equal volume of 2% formic acid in water.  Free AMC liberated by Cathepsin-B is 1339	
quantitated on a Sciex 5500 QTRAP mass spectrometer (Sciex, Framingham, MA) 1340	
equipped with a Biocius Rapidfire high-throughput LC system (Agilent, Santa Clara, CA).  1341	
AMC product is captured on an Agilent C18 Rapidfire cartridge, desalted with a 0.1% 1342	
formic acid wash, and then eluted with 80% acetonitrile, 0.1% formic acid.  Measured 1343	
MRM AUC for AMC is plotted against compound concentration using GraphPad Prism 1344	
(GraphPad Software, La Jolla, CA) and fitted for IC50 using four parameter fitting.  MRM 1345	
parameters for AMC: ESI positive mode, Q1=233.1, Q3=175.2, collision energy=16. 1346	
 1347	
Caspase-3 protease assay.  Caspase-3 proteolytic activity is quantitated by an LC/MS, 1348	
MRM-based detection method.  Briefly, varying concentrations of experimental 1349	
compound are incubated with 0.025 nM of recombinant Caspase-3 (cloned and purified 1350	
in-house) and 1 µM (Z-DEVD)2-Rho110  fluorogenic substrate in buffer containing 25 1351	
mM Hepes, pH 7.2 and 5 mM DTT.  The reaction is incubated for 20 minutes at room 1352	
temperature, followed by quenching with the addition of an equal volume of 2% formic 1353	
acid in water.  Free Z-DEVD liberated by Caspase-3 is quantitated on a Sciex 5500 1354	
QTRAP mass spectrometer (Sciex, Framingham, MA) equipped with a Biocius Rapidfire 1355	
high-throughput LC system (Agilent, Santa Clara, CA).  Z-DEVD product is captured on 1356	
an Agilent C18 Rapidfire cartridge, desalted with a 0.1% formic acid wash, and then 1357	
eluted with 80% acetonitrile, 0.1% formic acid.  Measured MRM AUC for Z-DEVD is 1358	
plotted against compound concentration using GraphPad Prism (GraphPad Software, La 1359	
Jolla, CA) and fitted for IC50 using four parameter fitting.  MRM parameters for Z-DEVD: 1360	
ESI negative mode, Q1=609.2, Q3=440.2, collision energy=-35. 1361	
 1362	
USP7 aggregation analysis.  Aggregation of full-length USP7 was confirmed by dynamic 1363	
light scattering (DLS) using a Wyatt DynaPro Plate Reader.  DLS data were acquired at 1364	
37°C, with Dynamics V7 software, with a 10 second acquisition time, 10 acquisitions per 1365	
measurement in auto-attenuation mode.  Compounds were present at 100µM in a buffer 1366	
containing 50mM HEPES pH 7.2, 150mM NaCl, 0.01% Triton X-100, 1mM TCEP, 0.1% 1367	
DMSO. Full-length USP7 was present at 1 mg/ml with all compounds except Rottlerin.  1368	
Aggregate is defined here as having a hydrodynamic radius greater than 10 nm. 1369	
 1370	
USP7 covalent modification and LC-MS analysis.  To evaluate potential covalent 1371	
modification of the proteins, full-length USP7 full-length was incubated with excess 1372	
compound at room temperature overnight and covalent modification was evaluated by 1373	
LC-MS using standard methods. 1374	
 1375	
Cell culture and cell treatments 1376	
HCT-116 parental, USP7 null (HD R02-028), and HCT-116 p53 null (Horizon; HD 104-1377	
001) cell lines were purchased from Horizon.  Normal cells were purchased from the 1378	
following vendors:  normal mammary cells (Life Technologies; HMEC A10565), normal 1379	
osteoblasts (Lonza; CC-2538) and were cultured in the vendor-specified media.  All 1380	
other cell lines were obtained from Genentech’s repository and were cultured in standard 1381	
conditions in RPMI media containing 10% FBS (solid tumor cell lines) or 20% FBS 1382	
(hematopoietic cell lines), 1% penicillin/streptomycin, and 1% L-Glutamine.  All cell lines 1383	
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were mycoplasma-tested and cell line identity was by STR and SNP profiling as 1384	
described26.  For studies evaluating cellular effects of compound treatments, 2,500-5,000 1385	
cells were seeded in 1-well of a 96-well plate (Corning; 3904). The following day, the 1386	
media was changed from normal (10%) to low serum (0.5%) containing vehicle (DMSO) 1387	
or compounds. Sixteen to 24 hours later FBS was added to each well to bring serum 1388	
levels back to 10%. Cells were then allowed to grow for two additional days.  All 1389	
treatments were done in triplicate.  For degradation rescue studies, the proteasome 1390	
inhibitor bortezomib (Selleckchem) or the UAE inhibitor MLN7243 (Active Biochem) were 1391	
added at 5µM 30-45 minutes prior to harvest. 1392	
 1393	
Cycloheximide chase studies   1394	
MCF-7 cells were treated for a total of 7 hours with DMSO or 15μM of the indicated 1395	
compounds.  During the 7 hours of compound treatment, 50µM cycloheximide was 1396	
added for the indicated times prior to harvest.  Cell lysates were subsequently processed 1397	
for western blot analysis. 1398	
 1399	
Antibodies and reagents  1400	
Antibodies to the indicated proteins were purchased from the following vendors:  USP7 1401	
(ab84098), USP5 (ab84695) [AbCam] or (4833) [Cell Signaling Technology]; MDM2 1402	
(Santa Cruz sc-965 or EMD Millipore 07-575); tubulin (LICOR 926-42211); tubulin-HRP 1403	
(5346), actin-HRP (12620), GAPdH-HRP (8884), caspase-3 (9662), PARP (9441), total 1404	
S6 (2217), phospho-S235/236-S6 (2945), Mcl-1 (4572), PIM2 (2730), cleaved-caspase-3 1405	
(2664), phospho-S112-Bad (5284), p21 (2947) [Cell Signaling Technology]; K48 1406	
polyubiquitin (Genentech); USP47 (Bethyl A301190A); UCHL1 (Invitrogen 38-1000); HA-1407	
HRP (clone HA-7) and FLAG (A8592) [Sigma]; p53 (Thermo Scientific MS738-P1); p21 1408	
(Millipore 05-655), Bad (AF819) [R&D].  Secondary antibodies were purchased from 1409	
LICOR Biosciences or Jackson Immunoresearch.  Full-length human USP7 was cloned 1410	
into a pRK5 mammalian expression construct with a C-terminal FLAG-tag and mutations 1411	
were introduced by QuickChange site-directed mutagenesis as instructed by the 1412	
manufacturer (Agilent). 1413	
 1414	
Western blotting, quantitation, immunoprecipitations, and deubiquitinase assays 1415	
Cells were treated with compounds as detailed above prior to lysis for Western Blot 1416	
analysis.  Primary antibodies were diluted 1:1000 and incubated 1 hour at room 1417	
temperature or 4ºC overnight.  Secondary antibodies were diluted 1:10,000 and 1418	
incubated 30-60 minutes at room temperature.  Blots were either imaged using a 1419	
chemiluminescent reagent (Pierce) or were scanned and bands were quantified using 1420	
LICOR Odyssey instrumentation and software, respectively.  Immunoprecipitations with 1421	
ubiquitin-specific antibodies were performed as described27 and immunoprecipitates and 1422	
corresponding cell lysates were analyzed by immunoblot analysis as previously 1423	
described27 using the antibodies detailed above.  For in vitro deubiquitination of PIM2, 1424	
ubiquitinated PIM2 was captured by treating MV-4-11 cells for 45 minutes with the 1425	
proteasome inhibitor MG-132 (SelleckChem).  Cells were washed, lysed in a 6M urea 1426	
lysis buffer, and anti-K48 polyubiquitin immunoprecipirates were washed and 1427	
deubiquitinated with 250nM wild-type or C223S full length recombinant USP7 following a 1428	
similar protocol as described27. 1429	
 1430	
Cell viability studies 1431	
IncuCyte live cell analysis.  One day after cell seeding, 10% cell culture media was 1432	
changed to 0.5% serum media containing 2μM CellEvent Caspase 3/7 reagent (Life 1433	
Technologies; C10423) and compounds.  The plates were placed in an IncuCyte live cell 1434	
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imager and scanning was started within 15-20 minutes.  Images were taken every 2 1435	
hours for 68-72 hours, using a 10X objective.  Phase contrast was used to measure cell 1436	
confluency/density while green fluorescence was used to measure caspase activity. The 1437	
images were analyzed using IncuCyte software (Basic Analysis parameters) and a ratio 1438	
of caspase activity to cell density/count was determined.  For combination experiments, 1439	
MCF7 cells were treated with 15µM USP7 inhibitors or 0.1µM doxorubicin alone or in 1440	
combination.  Similarly, U2OS cells were treated with 15µM USP7 inhibitors or 1µM 1441	
cisplatin alone or in combination. 1442	
 1443	
CellTiter-Glo assays (Extended Data Figures 1d, 1e, 2b) .  Seventy-two hours after 1444	
compounds were added, CellTiter-Glo (CTG, Promega) reagent was added following the 1445	
vendor protocol. Three times more USP7 null HCT-116 cells were plated per well than 1446	
wild-type HCT-116 cells (7,500 vs. 2,500 cells), given the slower proliferation of USP7 1447	
null cells.  For studies with multiple myeloma cell lines, cells were seeded in 0.5% serum 1448	
and treated with compounds immediately.  Twenty-four hours later, serum was added 1449	
back to normal levels.  CTG assay was done 24 hours later, i.e. 48 hours after 1450	
compounds were added instead of 72 hours later for the adherent cells.  1451	
 1452	
Tumor cell line panel viability studies.  GNE-6640 and GNE-6641 were profiled across 1453	
441 cell lines as previously described28. In brief, compounds were screened in 9-point 1454	
dose response using a 3-fold dilution. Cells were seeded into 384 well plates 24 hours 1455	
prior to compound addition.  Cells were then incubated with compound for 72 hours or 1456	
120 hours before assaying viability (CellTiter-Glo, Promega). Assays were performed in 1457	
biological triplicate. Cells were incubated (37 °C, 5% CO2) in RPMI-1640, 2.5% FBS (72 1458	
hour assay) or 5% FBS (120 hour assay), and 2 mM glutamine throughout the assay. 1459	
The reported IC50 and mean viability metrics are as follows:  IC50 is the dose at which the 1460	
estimated inhibition is 50% relative to untreated wells (i.e. absolute IC50). The mean 1461	
viability statistic is the arithmetic average of the fitted viabilities at each tested dose. 1462	
Mean viability is equivalent to the area under the log-dose/viability curve divided by the 1463	
total number of tested doses, and is thus on an interpretable percentage scale. 1464	
 1465	
Exome-Seq pipeline.  FASTQ reads were aligned to the human reference genome 1466	
(GRCh38) using GSNAP (PMID:20147302, 27008021) version ‘2013-10-10’ using the 1467	
following parameters: -M 2 -n 10 -B 2 -i 1 --pairmax-dna=1000 --terminal-threshold=1000 1468	
--gmap-mode=none --clip-overlap.  Duplicate reads in the resulting BAM file were 1469	
marked using PicardTools, and indels realigned using the GATK IndelRealigner tool. 1470	
Variations were called using the Bioconductor package VariantTools version 1.9.4. using 1471	
default options except for two exceptions: 1) no variants were called in repeat regions as 1472	
defined by the annotation Dust, Satellite repeats, and Tandem repeats in EnsEMBL 77 1473	
and 2) the avgNborCount post filter was configured using all SNPs from dbSNP version 1474	
138. 1475	
Mean viability analysis.  We determined genomic and non-genomic features that were 1476	
associated with differences in compound sensitivity. Mean viability is calculated as the 1477	
arithmetic average of the fitted viabilities at each tested dose, as previously described28. 1478	
For this analysis, normalized mean viabilities of GNE-6640 and GNE-6446 were 1479	
determined by normalizing the mean viabilities of each compound by the mean viability 1480	
of GNE-6641.  Cancer type, cell histology, loss-of-function and hotspot mutations were 1481	
assessed for statistical association with changes in normalized mean viability. Loss-of-1482	
function protein coding mutations include: 1) insertions, 2) deletions, and 3) substitutions 1483	
resulting in predicted truncating, splice site, translational start site, or non-stop mutations 1484	
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present in greater than 90% of reads sequenced (> 90% variant allele frequency). 1485	
Hotspot missense mutations assessed here were previously reported as significantly 1486	
recurrent mutations in a pan-cancer analysis (PMID: 26619011). Features present in at 1487	
least 3 cell lines were assessed. Statistical significance was determined using two-sided 1488	
Student’s t-Test.  Q-values were determined by correcting resulting p-values for multiple 1489	
hypothesis testing using Benjamini and Hochberg. 1490	
Primary combination screen.  A compound library comprising 589 compounds arrayed in 1491	
9 point dose response was screened in the absence or presence of fixed doses of GNE-1492	
6776 (0 nm, 125 nM, 250 nM, 500 nM, 1000nM, and 2000 nM) or GNE-6640 (400 nM).  1493	
Briefly, 5,000 EOL-1 cells were seeded into 384 well plates, and compound was added 1494	
24 h later. Cell viability was determined 120 h post-compound addition (CellTiter Glo). 1495	
Curves were fitted, and both IC50 and mean viability metrics were calculated. The IC50 is 1496	
the dose at which inhibition is 50% relative to untreated wells. The mean viability is the 1497	
average of the fitted viabilities at each tested dose.  Mean viability is equivalent to the 1498	
area under the log-dose/viability curve divided by the total number of tested doses. 1499	
Mean viability values were used for the analysis described in Extended Data Figure 6d.  1500	
All data were fitted using Genedata Screener (GDS) software.   1501	
Primary combination screen analysis.  We determined normalized mean viabilities in the 1502	
EOL-1 cell line for 574 compounds with a known protein or mechanistic target either in 1503	
the presence of DMSO or increasing concentrations of GNE-6776 (100 nM, 250 nM, 500 1504	
nM, 1000 nM or 2000 nM) or 400 nM of GNE-6640. For each compound we assessed 1505	
the difference in mean viability between USP7-inhibitor treatment versus the DMSO 1506	
treatment.  For targets targeted by 3 or more compounds we calculated the enrichment 1507	
of high mean viability difference for each concentration of USP7 inhibitor by using the 1508	
Wilcoxon rank sum test.  For visualization purposes we combine the results of all 1509	
concentrations by taking the mean of the -log10 transformed p-values for each target. 1510	
Bliss Analysis.  PIM inhibitors were tested in a 9-point dose response matrix with GNE-1511	
6676 in the same manner as described for the compound library screen.  Inhibitors were 1512	
screened in 3-fold dilution using a top concentration of 10 µM for PIM inhibitors and 20 1513	
µM for GNE-6676.  Bliss calculations were performed in GDS.  1514	
 1515	
Deubiquitinase selectivity analysis 1516	
Recombinant deubiquitinase di-ubiquitin mass spec cleavage assay. The MALDI-TOF 1517	
DUB assay was performed using the indicated concentrations of recombinant 1518	
deubiquitinases, di-ubiquitin substrates, and USP7 inhibitor compounds as previously 1519	
described4. The inhibition efficiency for GNE-6640 and GNE-6776 against the UCHL 1520	
family members was monitored on an alternative substrate, Ub-Ube2W (Ub-E2), since 1521	
UCHL1, -3, and -5 and BAP1 are inactive against ubiquitin dimers of all linkage types29. 1522	
 1523	
Endogenous deubiquitinase activity-based probe assay.  293T cells at 80% confluency 1524	
were harvested by rinsing the plate once with 10 mL PBS followed by scraping. Cells 1525	
were cleared by spinning them for 3 min at 350 g at 4°C and cell pellets were flash-1526	
frozen in liquid nitrogen and stored at –80 °C until lysis.  Frozen pellets were lysed by 1527	
quickly re-thawing them in Buffer A (50 mM Tris-HCl pH 7.5, 250 mM Sucrose, 1x 1528	
Phosphatase STOP, 2.5 mM TCEP, 2 mM ATP, 50 µM phenylmethylsulfonyl fluoride 1529	
(PMSF), 120 mM NaCl, 5 mM MgCl2) and the lysate was cleared by centrifugation by 1530	
spinning at 18,000 g at 4°C. The protein concentration was adjusted to 5 mg/mL, and 5 1531	
mg (1 mL) each of this cell lysate was incubated with indicated compounds or DMSO at 1532	
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the indicated concentrations for 20 min at 900 rpm, 25 °C in a Thermomixer® 1533	
(Eppendorf AG). After compound incubation, 300 ng recombinant viral DUB was added 1534	
and lysates were incubated with 6.6 µg/mL of the indicated activity-based DUB probe, 1535	
1250 rpm, at 25°C, for the indicated times. The reaction was terminated by adding a 1536	
20% SDS solution to a final concentration of 0.4% for at least 30 min at room 1537	
temperature, rotating.  Subsequently, the lysate was diluted 10x with Buffer B (50mM 1538	
Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, protease inhibitor cocktail EDTA-free 1539	
(Roche, Mannheim, Germany), 50 µM PMSF, 0.5 % NP-40) into 15 mL conical tubes. ~ 1540	
120 µL slurry of pre-equilibrated anti-HA affinity matrix (Roche, Mannheim, Germany) 1541	
was added and HA-tagged proteins were immunopurified with this matrix by rotating the 1542	
samples overnight at 4 °C. The beads were then washed 1 mL of ice-cold Buffer B (3x), 1543	
Buffer B without NP-40 (1x), and TEAB (15 mM Triethylammoniabicarbonate, pH 8.5) 1544	
(3x). Spins between washes were performed at 2000 g at 4°C. To elute the 1545	
immunopurified material 330 µL of Buffer C (1 mg/mL HA peptide (Thermo Scientific, 1546	
Waltham, MA), 15 mM TEAB, 0.02 % Rapigest® (Waters, Milford, MA)) was added and 1547	
the samples were incubated at 37°C for 30 min at 1100 rpm shaking in a Thermomixer® 1548	
(Eppendorf AG). The eluted material was cleared from the beads by spinning at 2600 g. 1549	
The cleared material was stored at –80 °C until mass spectrometry preparation and 1550	
analysis. For DUB identifications the eluted proteins were digested with trypsin using 1551	
filter-aided sample preparation (FASP). Eluents were added to Microcon-30K filtration 1552	
devices (Millipore, Billerica, MA) and briefly washed by 0.2 mL of 8 M urea in 200 mM 1553	
TEAB, pH 8.5. In between each step, liquid was cleared by centrifugation at 14,000 xg, 1554	
except if noted. Proteins were reduced by Dithiothreitol (DTT) for 20 minutes at 60°C 1555	
and subsequently alkylated by iodoacetamide (IAA) for 15 minutes in the dark. The 1556	
membrane was further washed by 8 M urea once and 200 mM TEAB three times. 1557	
Trypsin (Promega, Madison, WI) was added at 1:40 enzyme/substrate ratio. Devices 1558	
were briefly centrifuged at 100 xg for 30 seconds and incubated overnight at 37°C. 1559	
Tryptic peptides were recovered by centrifugation at 14,000 xg for 4 minutes. An 1560	
additional 60 μL of 200 mM TEAB, pH 8.5 was added to the devices and centrifuged as 1561	
an additional elution step. This eluent was combined with the previous for further 1562	
processing. Ten percent of the eluents were dried in speedvac and desalted with a C18 1563	
STAGE tip (Proxeon, Thermo Fisher) before injected onto the mass spectrometer for LC-1564	
MS/MS acquisition. 1565	
 1566	
Deubiquitinase identification by mass spectrometry.  Peptides were loaded onto an 1567	
Acuity UPLC® BEH130 C18 column (1.7 μm, 12Å, 100 μm x 100 mm) at a flow rate of 1568	
1.5 μL/min in solvent A (98% water/2% MeCN/0.1% formic acid) using a NanoAcquity 1569	
UPLC system (Waters, Milford, MA). Separation was achieved with a linear gradient of 1570	
2% Solvent B (98% MeCN/2% water/0.1% formic acid) to 25% Solvent B over 45 1571	
minutes. Eluted peptides were injected onto an Orbitrap Elite mass spectrometer 1572	
(Thermo Fisher, San Jose, CA) using an Advance CaptiveSpray source (Bruker, Auburn, 1573	
CA) at a voltage of 1.2kV. Full MS scans were collected in the orbitrap at 60,000 1574	
resolution and the top 15 most abundant ions were selected in a data dependent mode 1575	
and fragmented with CID and ms/ms were collected in the ion trap.  MS/MS spectra 1576	
were searched using Mascot (v.2.3.02) against a human proteome database (Uniprot 1577	
Dec. 2011) with known contaminants along with all decoy sequences. Search 1578	
parameters included trypsin cleavage allowing up to 2 missed cleavage events, a 1579	
precursor ion tolerance of 50 ppm, and a fragment ion tolerance of 0.8 Da. Searches 1580	
also permitted variable modifications of methionine oxidation (+15.9949 Da), and two 1581	
cysteine modifications of either (+57.0215) for carbamidomethylation or (+192.0569 Da) 1582	
for reacted DUB probe remnant, Peptide spectra matches were filtered with a false 1583	
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discovery rate (FDR) of 5% on the peptide level and subsequently at 2% on the protein 1584	
level.  Each identified peptide-spectrum match (PSM) was quantified using the area 1585	
under curve and same quantification event was extended to other runs where such 1586	
peptide was not identified by an ms/ms spectrum, based on exact precursor m/z and 1587	
retention time matching. 1588	
 1589	
Statistical analysis of deubiquitinase activity data.  Detected and quantified area-under-1590	
curve (AUC) measures from label-free mass spectrometry were logarithmically (base 2) 1591	
rescaled.  Changes between inhibitor- and control-treated lysate were compared via a 1592	
linear mixed effects model with fixed effects for treatments and random effects for 1593	
peptide species and mass-spec run.  Computations were performed in R, version 3.3.0 1594	
using the R package lme4, with error degrees of freedom estimated via the Kenward-1595	
Roger method using the R package pbkrtest.  For each protein, log2 fold change in 1596	
activity was normalized to that observed in a spiked-in viral DUB or BSA control protein.  1597	
Statistical significance of the observed “inhibitor-vs-control” differences in log2 fold 1598	
change between each DUB and the control protein was then assessed via a t-statistic 1599	
with Satterthwaite-estimated degrees of freedom, and corrected for multiplicity via the 1600	
Benjamini-Hochberg False-Discovery Rate method (FDR) set at 0.10. 1601	
 1602	
Animal use and care 1603	
All animal work followed the recommendations of the Guide for Care and Use of 1604	
Laboratory Animals with respect to restraint, husbandry, surgical procedures, feed and 1605	
fluid regulation, and veterinary care.  The animal care and use program at Genentech is 1606	
accredited by the Association for Assessment and Accreditation of Laboratory Animal 1607	
Care International (AAALAC), which assures compliance with accepted standards for the 1608	
care and use of laboratory animals.  Studies were tailored to minimize the number of 1609	
animals used, yet sufficient numbers to address any variability in drug exposure or 1610	
biomarker response.   Due to the need to monitor potential adverse effects with first in-1611	
life assessment of novel compounds, no study was conducted under blinded conditions. 1612	
 1613	
DMPK analysis 1614	
In vitro DMPK studies were performed using standard protocols.  GNE-6776 was 1615	
formulated as a suspension in 0.5% methylcellulose/0.2% Tween-80 (MCT) and was 1616	
administered at 200 mg/kg by oral gavage to female C.B-17 SCID mice, age 12 – 16 1617	
weeks (Charles River Labs; n=3 per time point).  At 0.5, 1, 2, 4, 8 and 24 hours post-1618	
dose, blood samples were collected by terminal cardiac puncture into anticoagulant 1619	
tubes (EDTA).  Clarified plasma was then transferred to a fresh tube and snap frozen.  1620	
GNE-6776 plasma concentrations were determined by LC/MS-MS. 1621	
 1622	
In vivo pharmacodynamic response 1623	
For EOL1 acute myeloid leukemia xenograft studies, immunodeficient C.B-17 SCID mice 1624	
(Charles River Labs), aged 12 - 16 weeks, were inoculated subcutaneously on the right 1625	
flank with five million cells in a 50:50 suspension of HBSS:Matrigel (BD Biosciences; 100 1626	
µL).  When tumor volumes reached between ~285-500 mm3, mice were distributed into 1627	
volume-matched cohorts (n=4).  For MCF7 breast cancer xenograft studies, 1628	
immunodeficient nu/nu mice (Charles River Labs), aged 6-8 weeks, were implanted with 1629	
0.36 mg estrogen pellets (Innovative Research of America) via trochar 1-3 days prior to 1630	
tumor cell inoculation. Ten million MCF7-Ser cells, an in vivo-optimized MCF7 variant, 1631	
were injected orthotopically into the 2/3 mammary fat pad of each mouse in a 50:50 1632	
suspension of HBSS:Matrigel (BD Biosciences) in a total volume of 100 µL.  When tumor 1633	
volumes reached between ~285-450 mm3, mice were distributed into volume-matched 1634	
	 35	
cohorts (n=4).  GNE-6776 was formulated as a suspension in 0.5% 1635	
methylcellulose/0.2% Tween-80 (MCT) and was administered at 200 mg/kg by oral 1636	
gavage at zero and four hours. MCT control or GNE-6776-treated samples were 1637	
collected at eight hours following the first dose and excised tumors were flash-frozen on 1638	
dry ice.  Tumors were lysed in RIPA buffer containing protease inhibitors (Roche) and 1639	
300 mM NaCl using a Qiagen Tissuelyser.  Samples were incubated on ice for 15 1640	
minutes and then centrifuged at 20,000 x g at 4˚C for 10 minutes.  Protein levels in 1641	
clarified lysates were quantified using a Pierce BCA assay kit and concentrations were 1642	
normalized with sample buffer.  Samples were run on gels and proteins were transferred 1643	
to membranes and western blotted as described above. 1644	
 1645	
In vivo efficacy study 1646	
For EOL1 acute myeloid leukemia xenograft studies, immunodeficient C.B-17 SCID mice 1647	
(Charles River Labs), aged 12 - 16 weeks, were inoculated subcutaneously on the right 1648	
flank with five million cells in a 50:50 suspension of HBSS:Matrigel (BD Biosciences; 100 1649	
µL).  When tumors became established (150 – 300 mm3), mice were distributed into 1650	
tumor volume-matched cohorts (n=7, mean tumor volume ~250 mm3).  GNE-6776 was 1651	
formulated as a suspension in 0.5% methylcellulose/0.2% Tween-80 (MCT) and was 1652	
administered at 100 or 200 mg/kg by oral gavage on a once or twice daily schedule.  1653	
Tumor volume measurements, body weight and condition data was collected 2-3 times 1654	
per week.   1655	
 1656	
USP7 enzymatic analysis  1657	
Michaelis-Menten kinetic measurements with full-length USP7 were carried out using 1 1658	
nM USP7 with a series of ubiquitin-AMC substrate titrations with at least three technical 1659	
replicates. Initial rate of substrate hydrolysis was determined using the Magellan 1660	
software on a Tecan Safire2 plate reader and kinetic parameters modeled using 1661	
nonlinear regression analysis with GraphPad Prism software. Standard error was 1662	
calculated from multiple experimental replicates.  For studies using the USP7 1663	
D305/E308 mutant, samples were reacted in a buffer consisting of 50 mM HEPES (pH 1664	
7.5), 100 mM NaCl, 2.5 mM Dithiothreitol, 0.1% (w/v) bovine gamma globulin (Sigma cat 1665	
# G5009-25G).  The starting substrate concentration of Ubiquitin-Rho110 (Boston 1666	
Biochem cat # U-555) used for the Michaelis-Menten analysis was 100 μM serial diluted 1667	
to 781 nM. Reactions were carried out for 1 hour at room temperature with a final 1668	
enzyme concentration of 100 nM (three independent experiments, see symbols in plot), 1669	
in a black 100 μL volume 96 well half area plates (Corning cat # 3993).  The enzymatic 1670	
activity was calculated by fitting the data using the initial velocity using the linear V0 1671	
values measured by analyzing the fluorescence signal of cleaved Rho-110 using 1672	
excitation at 485 nm and emission at 535 nm. 1673	
  1674	
X-Ray crystallography 1675	
Crystals were grown by the hanging-drop method by mixing the USP7 catalytic domain 1676	
(residues 208–554) at 15 mg/ml with an equal volume of reservoir solution containing 1677	
100 mM Tris,-HCl, pH 7.0, and 20% PEG1000 (v/v). Co-structures with compounds were 1678	
obtained by soaking crystals with 1 mM of compound overnight. Crystals were 1679	
cryoprotected with reservoir solution supplemented with 20% glycerol (v/v) and flash 1680	
frozen in liquid nitrogen. Data collection and refinement statistics are detailed in 1681	
Extended Data Fig. 7d. 1682	
 1683	
Generation of isotopically-labeled di-ubiquitins 1684	
	 36	
Ubiquitin was cloned into a peT3a vector and transformed into the auxotrophic strains 1685	
RF2 and ML2 (a kind gift from Robert Gennis and Toshio Iwasaki)	30 and expressed 1686	
with the following modifications:  Bacterial cultures were grown at 37°C in M9 media 1687	
supplemented with NH4Cl (2 g/L), C6-glucose (4 g/L).  Strain RF2 was additionally 1688	
supplemented with 6mM 15N L-Thr (Cambridge Isoptopics Cat#NLM-142-PK) and ML2 1689	
were supplemented with 6mM 15N L-Leu (Cambridge Isoptopics Cat#NLM-142-1) and 6 1690	
mM unlabeled Ile and Tyr (Sigma-Aldrich Cat# I2752 and Cat# T3754). After reaching 1691	
an OD of 0.6 the cells were induced with 1 mM IPTG and further grown for 6 hours.  1692	
Protein purification was performed at room temperature. Cells were harvested and 1693	
lysed in lysis buffer (50 mM HEPES 7.0). The cleared lysate was subjected to affinity 1694	
chromatography using DEAE sepharose Fast Flow (GE Cat# 17-0709-01). Ubiquitin 1695	
was collected in the flow through and dialyzed overnight into NaOAc pH 4.5. Dialyzed 1696	
material was clarified by centrifugation at 35K and ubiquitin was subjected to ion 1697	
exchange chromatography (IEX) using a MonoS column (GE Healthcare, Cat# 17-1698	
5169-01). The following enzymes were obtained from Boston Biochem Cambridge, 1699	
UBE1 (Cat# E-305), UBE2K and UBE2N/UBE2V1 complex (Cat# E2-602 and Cat# E2-1700	
664) respectively. K63- and K48-linked di-ubiquitin chains were generated and purified 1701	
as follows:  In separate reactions incubating 250 nM E1 enzyme, 5 μM UBE2K (K48 1702	
linked) or 5 μM UBE2N/UBE2V1 complex (K63 linked) with equal molar ratios of 1 mM 1703	
ubiquitin and 1 mM ubiquitin, 10 mM ATP, 50 mM HEPES (pH 8.0), 10 mM MgCl2 in a 1704	
10 mL reaction at 37 °C.  After 2 hours, the reaction was acidified with 2 mL of 17.4 M 1705	
Glacial Acetic Acid.  Obtained di-ubiquitins (K63- or K48-linked) were purified by cation 1706	
exchange using a MonoS column (GE Healthcare, Cat# 17-5169-01).  All purified di-1707	
ubiquitin chains were buffer exchanged into 1x PBS buffer and proteins were flash 1708	
frozen in liquid nitrogen prior to storage at −80°C. 1709	
Generation of 5-TAMRA-peptide/tetra-ubiquitin conjugates  1710	
K63- and K48-linked tetra-ubiquitin chains were obtained from Boston Biochem 1711	
Cambridge, K63-linked (Cat# UC-310B), K48-linked (Cat# UC-210B).  The 5-TAMRA  1712	
(5-Carboxytetramethylrhodamine) peptide was generated by CPC-Scientific consisting of 1713	
the sequence 5-TAMRA-YPYDVPDYAIREIVSRNKRRYQEDG20. K63 or K48 tetra-1714	
ubiquitin chains were conjugated to the peptide as follows: (1) Generation of tetra-1715	
ubiquitin-MESNA; incubating 250 nM E1, 10 mM MgCl2, 10 mM MgATP, 1 mM tetra-1716	
ubiquitin, 100 mM MESNA (Sigma Aldrich, Cat# 63705), in 20 mM Na2HPO4 at pH 8.0 at 1717	
37˚C overnight. Dialyzed into 0.4% TFA and tetra-ubiquitin-MESNA was lyophilized.  (2) 1718	
Lyophilized tetra-ubiquitin was dissolved in DMSO at a concentration of 0.5 mM and 2 1719	
mg of peptide were added until all components were dissolved, reaction volume 1 mL. 1720	
The reaction was initiated by adding (final concentrations) NHS 27.5 mM, AgNO3 3.3 1721	
mM, and 22 µl DIPEA and incubated at RT overnight.  The reaction was diluted 10X with 1722	
ddH2O and desalted into PBS pH 7.5.  Non-conjugated peptide was removed by size 1723	
exclusion (SEC) chromatography.  In a second step non-conjugated tetra-ubiquitin was 1724	
removed by IEX chromatography as described above and buffer exchanged into 1x PBS 1725	
(pH 7.5). The concentration of the purified final conjugate was determined by 1726	
absorbance using an extinction coefficient for 5-TAMRA at 80,000 cm-1M-1.  1727	
 1728	
TAMRA-peptide/tetra-ubiquitin conjugate depolymerization studies 1729	
For depolymerization assays, 100 nM USP7 (cat# E-519, lot#09939314) or 100 nM 1730	
USP7 catalytic domain N-terminal His-tag (Genentech, Hs_USP7.K208-K554) were 1731	
diluted in 1x PBS buffer (pH 7.5) containing 5 mM DTT to generate 10x stock solutions in 1732	
respect to the final concentration and preincubated at room temperature for 10 minutes. 1733	
In a 90 µL reaction, 9 µg (2.7 µM) of 5-TAMRA-peptide/tetra-ubiquitin (K63- or K48-1734	
	 37	
linked) was mixed with 9 µL of diluted enzyme in 1 x PBS buffer (pH 7.5). Aliquots of 10 1735	
µL of the reaction were mixed with 4 µL 2x SDS loading buffer at the time points 1736	
indicated to stop the reaction.  Samples (14 µL) were subjected to SDS gel-1737	
electrophoresis using precast BioRad Criterion TGX 10-20% gels (cat# 5671114).  1738	
Fluorescence was analyzed using the FluorChem imager from Protein Simple according 1739	
to the user manual.  Densitometry values were analyzed using the software 1740	
AlphaViewSA, ProteinSimple. 1741	
––
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Cluster 1 1 2 3 3
% Inhibition Primary 
Screen 76.8 76.3 66.4 53.3 50.1
UbA10 IC50 ( M) 1.17 1.37 > 49.5 2.58 2.79
diUb IC50 ( M) 0.36 0.49 6.42 2.49 1.53
Ub-Rho110 IC50 ( M) 0.29 0.31 2.16 2.65 N/D
MS Activity IC50 ( M) 0.13 0.15 14.87 0.5 0.61
MS Activity Hill Slope 0.83 1.06 1.02 0.87 1.12
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Compound GNE-0300 GNE-8735 GNE-3086 GNE-2090 GNE-6831 GNE-2916
Full Length 
USP7 IC50 (µM) 1.03 0.47±0.39 8.80±5.20 4.64±1.38 0.75±1.30 2.63±0.43
USP7 Catalytic 
Domain IC50 (µM) 1.40 0.50±0.31 13.80 41.7±30.6 >200 1.40±0.18
Full Length 
USP5 IC50 (µM) 160 >200 >100 >200 N/D >200 
Full Length 
USP47 IC50 (µM) 140 >200 7.0 63.3 >200 >200
Total MDM2 
increase (IF)
none
>20µM
increase
2.9µM
none 
>20µM
none
>20µM
none
>20µM
none
>20µM
Ub-MDM2 
MSD (µM) not done >50.00 9.65±3.18 3.55±1.91 3.20±2.69 7.60±0.57
Cathepsin-B
Inhibition (µM) > 40.00 6.12 not done not done > 40.00 not done
Caspase-3 
Inhibition
apparent 
precipitator
apparent 
precipitator not done not done not done not done
Dynamic Light 
Scattering pass pass pass pass pass not done
Covalent 
Modiﬁcation not done not done yes not done yes not done
TetrahydroacridinePeptidomimeticIndole tricyclic Fragment
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Compound GNE-2916 GNE-2931 GNE-9603 GNE-2917
Full Length 
USP7 IC50 (µM) 2.63±0.43 >200 >200 
USP7 Catalytic 
Domain IC50 (µM) 1.40±0.14 N/D >200 
Full Length 
USP47 IC50 (µM) >200 >63.3 109 
Full Length 
USP5 IC50 (µM) >200 N/D >200 
Ub-MDM2 
MSD (µM) 7.60±0.57 N/D N/D 
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Full Length 
USP7 IC50 (µM) 0.75±0.13 4.64±1.38 >200 196 
USP7 Catalytic 
Domain IC50 (µM) >100 41.7±30.6 >200 >200 
Full Length 
USP47 IC50 (µM) >200 >200 >200 N/D 
Full Length 
USP5 IC50 (µM) N/D >200 >20 >20 
Ub-MDM2 
MSD (µM) 30.8±11.1* 24.2±12.3* N/D N/D 
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>63 
N/D 
GNE-9603 
d.
Ce
llT
ite
r-G
lo 
sig
na
l
(%
 ve
hic
le 
co
nt
ro
l) 
concentration (µM)
GNE-0956
GNE-6831
GNE-2090
0 5.0 10.0 15.0 20.0 25.0
0
50
100
125
75
25
concentration (µM)
GNE-2917
GNE-2916
0 5.0 10.0 15.0 20.0 25.0
0
50
100
125
75
25Ce
llT
ite
r-G
lo 
sig
na
l
(%
 ve
hic
le 
co
nt
ro
l) 
GNE-2931
GNE-29160
50
100
125
75
25
0.0 2.5 5.0 7.5 10.0 12.5
GNE-9603
114
66.8
>200 
>20 
N/D 
AMO-1 cells KMS12-PE cells
inactive control compoundsactive compounds
inactive control compoundsactive compound
Kategaya et al. Supplementary Information Figure 6
a. GNE-6640 GNE-6776
MW/LogD7.4/ tPSA 330.38/4.40/87.0 348.40/3.30/3.4/101
LM CLhep (h/r/m/d/c) 14/46/75/24/33 4.1/15/37/14/12
Hep CLhep (h/r/m/d/c) 16/45/68/24/39 9.4/39/44/18/33
PPB % (h/r/m) 99.6/98.7/99.0 97.3/93.4/93.4
MDCK Papp ratio (B to A, A to B) 0.83 (12.17, 14.7) 0.75 (12.06, 16.10)
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